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Type 2 diabetes mellitus (T2D) is characterized by chronic hyperglycemia and peripheral 
insulin resistance.  In response to elevated blood glucose levels, pancreatic β-cells release insulin 
which occurs in a biphasic manner.  First-phase insulin secretion occurs via the KATP channel-
dependent pathway during the first 10 minutes after a glucose load.  Second-phase insulin 
secretion, KATP channel-independent pathways, results in a slow and sustained release of insulin, 
which can last for several hours after a glucose load.  The mechanisms underlying KATP channel-
independent pathways remain incompletely understood.  It is suggested that anaperlosis, 
increased production of tricarboxylic acid (TCA) cycle intermediates, regulates second-phase 
insulin secretion.  Anaplerotic pathways involve the production of cytosolic α-ketoglutarate 
(αKG) that may enhance prolyl 4-hydroxlase (PHD) activity. PHDs are well-established 
regulators of the hypoxia response pathway.  However, PHD may play a role in insulin secretion 
with both short- and long-term effects through prolyl hydroxylation of key proteins.  Inhibition 
of PHD via dimethyloxalylglycine (DMOG) decreased oxygen consumption rate (OCR) in both 
INS-1 832/13 cells and primary mouse islets.  DMOG treated primary mouse islets demonstrated 
enhanced second-phase insulin secretion when stimulated with high glucose (HG).  
Intraperitoneal glucose tolerance tests (ipGTTs) in male C57BL/6J mice treated with DMOG 
revealed improved glucose tolerance during second-phase insulin secretion and improved insulin 
sensitivity during first-phase insulin secretion.  The results presented in this thesis reveal that 
PHD plays a role in both first- and second-phase insulin secretion and may be a potential target 
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Chapter 1: Introduction 
1.1 Diabetes mellitus 
1.1.1 Background 
The incidence of diabetes is increasing worldwide.  In 2014, 6.7% of Canadians 12 years 
of age or older reported to be diagnosed with diabetes, consisting of 7.5% for males and 5.8% for 
females.
1
 According to the World Health Organization (WHO), 422 million adults are living 
with type 1 diabetes (T1D) or type 2 diabetes (T2D) with 1.5 million deaths in 2012 related to 
diabetes complications and 2.2 million deaths related to elevated blood glucose levels.
2
 The 
incidence of diabetes cases has emphasized the need to develop effective treatment options and 
implement strategies to promote diabetes prevention through lifestyle changes. 
T1D is less common compared to T2D and is an autoimmune disorder that is commonly 
diagnosed in younger individuals.
3
 The immune system is unable to recognize autoantigens 
presented on β-cells, which include glutamic acid decarboxylase (GAD), insulin, insulinoma-
associated antigen-2 (IA2), and zinc transporter 8.
3,4  
B-lymphocytes produce autoantibodies 
directed against β-cell autoantigens.
3 ,4 
T-cells and macrophages target autoantibodies inducing 
inflammation by increasing cytokine levels.
3
 Increased levels of cytokines, such as tumor 
necrosis factor α (TNFα), interleukin-1β (IL-1β), and interferon γ (IFN-γ), suppress insulin 
secretion and result in β-cell dysfunction and apoptosis.
3
 Serum levels of these autoantibodies is 
indicative of T1D development, with the presence of multiple autoantibodies resulting in 
approximately 70% risk of T2D development.
4  
In contrast to T1D, T2D has a slower progression and accounts for 90% of all diabetes 
cases.
5,6
 T2D is associated with obesity resulting from nutrient overload from fat and refined 
carbohydrates, physical inactivity and a genetic predisposition.
3




factors for T2D include a body mass index (BMI) of ≥ 25 kg/m
2
; ethnicity, with a higher 
incidence in Native Americans, African-Americans and Hispanic Americans; age of ≥ 45 years; 




Glucose metabolism is the main stimulus for pancreatic β-cell insulin secretion where 
insulin demonstrates systemic effects in adipose tissue, skeletal muscle and liver.  Approximately 
98% of the pancreas mass consists of acinar tissue, which produces exocrine enzymes for 
digestion.
7
 The remaining 2% of the pancreas mass is the endocrine portion and consists of the 
islets of Langerhans.
5,7
 Pancreatic islets consist of α, β, δ, ε and γ cell types.
7
 β-cells secrete 
insulin; α-cells secrete glucagon, which increases hepatic glucose production during 
hypoglycemic conditions to increase blood glucose levels; δ-cells secrete somatostatin, an 
inhibitor of both insulin and glucagon; ε-cells secrete ghrelin, a hormone that increases appetite; 
and γ-cells secrete pancreatic polypeptide, a regulator for gastrointestinal secretion.
7
 Although 
islets consist of 2% of the pancreas, they are highly vascularized and receive 10-20% of the total 
blood flow.
5
    
Obesity from chronic over-nutrition and physical inactivity results in peripheral insulin 
resistance.
3
 Pancreatic β-cells respond to insulin resistance via insulin hypersecretion to maintain 
normal blood glucose levels, known as normoglycemia, which is between 4-6 mmol/L.
3,7,8
 In this 
prediabetes state, pancreatic β-cells undergo compensation involving increased β-cell mass, 
insulin biosynthesis and nutrient-stimulated insulin secretion.
3,5,8
 Susceptible β-cells begin to 
fatigue due to increased oxidative stress and endoplasmic reticulum (ER) stress from increased 
proinsulin, the precursor to insulin, production.  β-cell fatigue results in increased blood glucose 






Glucolipotoxicity, elevated blood glucose and lipid concentrations, peripheral and pancreatic 
inflammation and oxidative stress eventually leads to β-cell failure, β-cell apoptosis and T2D 
diagnosis.
5,7 
T2D is associated with chronic low-grade inflammation and is associated with increased 
pro-inflammatory cytokines, including TNFα, IL-1β, and IFN-γ in the periphery and in the 
pancreas, which are insulin secretion suppressors and lead to β-cell apoptosis.
3,5
  Throughout the 
progression of T2D, islet inflammation, glucolipotoxicity and ER stress resulting from increased 
insulin secretion during compensation ultimately leads to β-cell apoptosis and subsequent 
hyperglycemia.
5
 T2D is a complex disease, affecting peripheral tissues including the liver, 
skeletal muscle and adipose tissue that rely on insulin for anabolic pathways.
7
 There are several 
anti-hyperglycemic medications that work to restore normoglycemia through various 
mechanisms within the peripheral tissues and the pancreas. 
 
1.1.2 Treatment options 
Glycated hemoglobin (A1C) is considered the gold standard for the diagnosis of T2D.
9
 
Glycated hemoglobin is the binding of glucose to the amino group of valine on the β chain of 
hemoglobin.
10
 The binding of glucose to hemoglobin is correlated to blood glucose 
concentrations over 8 to 12 weeks.
10
 T2D is diagnosed when a patient displays A1C levels ≥ 
6.5%.
11
  Despite A1C values to be the gold standard for T2D, there are limitations due to 
differences in glucose metabolism and hemoglobin glycation between individuals.
9
 When A1C 
levels are ≥ 6.5%, lifestyle modifications through diet and exercise are initiated and anti-




commonly prescribed anti-hyperglycemic agent and can be used alone or in combinational 
therapy if A1C levels are not obtained.
12
 
Metformin, part of the biguanide drug class, is the first line of defense for the 
management of hyperglycemia.  Metformin decreases hepatic glucose production and glucose 
absorption in the small intestine, as well as, increases glucose uptake and utilization to restore 
normoglycemia.
12,13
 Metformin is involved in the phosphorylation and activation of AMP-
activated protein kinase (AMPK), increasing glucose uptake in skeletal muscle and liver for 
glucose storage and utilization.
13
 Double-blind placebo control clinical trials proved a significant 
effect for metformin on reducing blood glucose levels and after a three month period metformin 
was able to reduce A1C levels by approximately 1%.
14
 Metformin has been shown to work in the 
small intestine, liver and kidney via the liver specific organic cation transporter (OCT) 1 and 
kidney-specific OCT2.
12,13
    
Aside from metformin’s effects on restoring blood glucose levels, metformin may have 
other beneficial effects including cardiovascular protective effects via anti-inflammatory 
properties.
15,16
 Metformin has been shown to inhibit macrophage differentiation by AMPK 
activation, playing a beneficial role in the reduction of insulin resistance and atherosclerosis.
15
  
Metformin is the first anti-hyperglycemic agent prescribed as it presents the least side 
effects, including hypoglycemic events and weightgain.
16 
Metformin has also been shown to 
have beneficial effects on atherosclerosis, a complication that arises from chronic 
hyperglycemia.
16
 Metformin was found to reduce atherosclerosis in mice fed a high fat diet 
(HFD) by inhibiting angiotensin II type 1 receptor via AMPK.
17
   
Another class of anti-hyperglycemic agents includes the insulin secretogogue’s 




membrane, leading to depolarization and increased insulin secretion.
6
  Both sulfonylureas and 
meglitinides bind to the sulfonylurea receptor (SUR) subunits, SUR1 and SUR2, on the KATP 
channels.
18
 Sulfonylureas are glucose-independent, leading to continuous inhibition of KATP 
channels resulting in increased basal insulin secretion, which increases the risk for 
hypoglycemia.
18




Sulfonylureas are metabolized by cytochrome P450 (CYP) 2C9, whereas meglitinides are 
primarily metabolized by CYP 3A4.
20,21
 However, genetic variants of these liver enzymes lead to 
differences in efficacy and side effects.
20
   Despite the side effects of sulfonylureas, they have 
been found to reduce A1C levels by approximately 1.0 to 1.25%.
14 
Other anti-hyperglycemic agents work to improve insulin sensitivity in adipose tissue.  
Thiazolidinediones (TZD) target peroxisome proliferator-activated receptor-gamma (PPAR-γ) to 
promote adipocyte differentiation to recover insulin sensitivity.
6,22-24
 Aside from adipocyte 
differentiation, PPAR-γ also increases glucose transporter 4 (GLUT4) expression for glucose 
uptake in adipose tissue.
25
 PPAR-γ regulates TNFα, adiponectin and leptin, which all play a role 
in insulin sensitivity.
24,25
 Despite the beneficial effects of TZD’s in improving insulin sensitivity 
and its ability to significantly decrease A1C levels by approximately 1.25%, there are side effects 
including fluid retention, weight gain and congestive heart failure.
14,25
 Many TZDs have been 
removed from the market due to liver failure and only pioglitazone and rosiglitazone remain 
available.
24
  More recently, rosiglitazone was linked with increased risk of myocardial 
infarction.
24
   
Other anti-hyperglycemic agents work to decrease glucose absorption in the small 






 α-glucosidase is a small intestine brush border enzyme that breaks 1,4α-bonds, 
digesting starch and disaccharides to produce glucose.
26
 Acarbose inhibits the breakdown of 
starch and disaccharides, decreasing blood glucose levels and insulin secretion postprandially.
26 
Insulinotropic hormones, glucose-dependent insulinotropic peptide (GIP) and glucagon-
like peptide 1 (GLP-1), are gastrointestinal peptides secreted from small intestine endocrine 
cells.
24,27,28
 GIP and GLP-1 are secreted to increase glucose-stimulated insulin secretion 
(GSIS).
27
 GIP and GLP-1 have a short duration of action and are inactivated by the enzyme 
dipeptidyl peptidase-4 (DPP-4).
27
 GLP-1 is a potent insulinotropic hormone and GLP-1 agonists 
aid in sustaining insulin secretion.
24
 GLP-1 agonists significantly improve A1C levels, promote 
weight loss and have a low risk of hypoglycemia.
29
 There are numerous side effects including 
nausea, vomiting, and indigestion and is not suggested for patients with gastrointestinal 
diseases.
24 
DPP-4 cleaves at proline or alanine residues on the N-terminus of GIP and GLP-1.
24
 
DPP-4 inhibitors prevent the degradation of GLP-1 by DPP-4, sustaining GSIS and delaying 
hyperglycemia in T2D patients.
24,27,28
 DPP-4 inhibitors also work to increase cell proliferation 
and decrease cell apoptosis to maintain β-cell mass.
24,27,28
 Clinical trials reveal that DPP-4 
inhibitors show a moderate effect on A1C levels, decreasing A1C levels by approximately 
0.75%.
14
  DPP-4 inhibitors display a low risk for hypoglycemia and do not result in weight 
gain.
30
 However, randomized control trials assessing the risk of saxagliptin, a DPP-4 inhibitor, 
for heart failure found that patients who had a family history of cardiovascular disease treated 
with saxagliptin were more likely to develop heart failure compared to placebo controls.
30
  







The newest class of anti-hyperglycemic agents, sodium-dependent glucose transporter 2 
(SGLT-2) inhibitors, prevent glucose reabsorption from the kidneys and promote glucose 
excretion in the urine.
31-33
 Approximately 180 grams of glucose is filtered by the kidneys and 
almost all is reabsorbed by the kidneys via SGLT-2.
33
 Preventing glucose reabsorption decreases 
blood glucose levels, insulin levels and promotes weight loss.
32,33
 SGLT-2 inhibitors were also 
found to improve risk factors for cardiovascular disease including blood pressure, arterial 
stiffness, and dyslipidemia.
31
   
Although there are numerous beneficial effects of SGLT-2 inhibitors, there are several 
side effects and the long-term consequences of altered electrolyte balance that occurs with 
SGLT-2 inhibitors is unknown.
33
 As well, clinical trials consisting of patients treated with the 
SGLT-2 inhibitor dapagliflozin, reported a small number of cases of breast and bladder cancer 
33
  
Apart from the oral anti-hyperglycemic agents described above, insulin therapy has been 
primarily used as a treatment option for T1D to replace the loss of β-cell insulin secretion.
34
 
Although anti-hyperglycemic agents are effective at reducing A1C levels, typically between 
0.8% and 2.0%, more than half of T2D patients fail to maintain normoglycemia.
35
 In order to 
decrease the risk of diabetic complications that arise from chronic hyperglycemia, insulin 
therapy is introduced as an add on to oral medications to stimulate basal insulin secretion.
35,36
 
Insulin therapy includes mixed insulins or insulin coformulations targeting blood glucose levels 
in a fed and fasted state.
35
 If normoglycemia is not achieved then a combination of mixed 
insulins and rapid-acting insulin is introduced, which is injected before a meal targeting blood 
glucose levels in a fed state.
35
 Personalized treatment plans are required when introducing insulin 
therapy in combination with other anti-hyperglycemic agents, as the risk of hypoglycemia is 
increased, particularly with sulfonylurea treatment.
36




therapy work to improve insulin sensitivity and attain normoglycemia as measured by A1C 
levels.   
All treatment options work through different mechanisms of action, targeting the 
pancreas, skeletal muscle, liver and adipose tissue.  T2D is a highly complex disease affecting 
multiple tissues with the pancreas as the central organ for regulating glucose homeostasis.  
Sulfonylureas and meglitinides target first-phase insulin secretion in the pancreas to stimulate 
GSIS.  However, second-phase insulin secretion accounts for approximately 70% of total insulin 
secretion, emphasizing the need to investigate potential targets of second-phase insulin secretion 
for drug development.
37
     
1.2 Glucose-stimulated insulin secretion pathway 
1.2.1 KATP channel-dependent pathway 
GSIS from pancreatic β-cells is biphasic.  First-phase insulin secretion occurs within the 
first 10 minutes after a glucose load, whereas, second-phase insulin secretion displays a slow and 
sustained release of insulin for up to two to three hours after a glucose load.
38
 The well-studied 
model of insulin secretion begins with increased blood glucose levels.  Glucose is taken up by 
glucose transporter 2 (GLUT2) in the pancreas and is metabolized generating pyruvate, which 
feeds into the tricarboxylic acid (TCA) cycle.
38-41
 Pyruvate can enter the TCA cycle via pyruvate 
dehydrogenase (PDH) or pyruvate carboxylase (PC).
38-41 
This subsequently leads to an increase 
in the ATP/ADP ratio, which closes the ATP-sensitive K
+
-channels causing membrane 
depolarization.
38-41
 Membrane depolarization opens voltage-gated calcium channels and allows 
for an influx of calcium ions.  Increased intracellular calcium ions causes insulin granule 
exocytosis.
38-41  
Insulin granules that are in close proximity to the plasma membrane and are 






The release of this readily releasable pool of insulin granules is regulated by 
the KATP channel-dependent pathway or the “triggering pathway”.
39,40
 The KATP channel-
dependent pathway is critical for first-phase insulin secreton.
38-40
 Second-phase insulin secretion 
may either stimulate the production of new insulin granules, or exocytosis of a larger pool of 
insulin granules located further from the calcium channels.
42
 It is suggested that the KATP 













Figure 1.1: KATP channel-dependent pathway. 
A schematic representation of the KATP channel-dependent pathway is shown above.  Two 
pyruvate molecules are produced from one molecule of glucose via glycolysis in the cytosol.  
Pyruvate enters the mitochondrial matrix via mitochondrial pyruvate carrier (MPC) and enters 
the TCA cycle via PDH or PC.  The TCA cycle generates cofactors that enter the electron 
transport chain (ETC) to pump protons into the intermembrane space forming the proton motive 
force.  Protons enter the mitochondrial matrix via ATP synthase to generate ATP.  Increased 
ATP/ADP leads to an influx of calcium ions and insulin granule exocytosis from the ‘readily 
releasable pool’.  Illustration reproduced courtesy of Dr. Jamie Joseph. 
 
 1.2.2 KATP channel-independent pathways 
 KATP channel-independent pathways, also called “amplifying pathways”, are suggested to 
regulate second-phase insulin secretion.
43




intermediates and is suggested to be important for second-phase insulin secretion.
43
 Pyruvate 
produced via glycolysis in the cytosol can enter the TCA cycle by PDH to produce acetyl-CoA 
or PC to produce oxaloacetate, a substrate in the TCA cycle.
37,44
 PDH and PC are expressed in 




 Oxaloacetate production by PC leads to the conversion of TCA cycle intermediates 
including citrate, isocitrate and malate.
37
 These TCA cycle intermediates translocate to the 
cytosol with subsequent reconversion to pyruvate.
37 
This “pyruvate cycling” produces by-
products αKG and NADPH that may stimulate insulin secretion and involves three pyruvate 
cycling pathways.
37,45,46
 The malate/pyruvate and the citrate/pyruvate pathways produce NADPH 
via malic enzyme, whereas, the isocitrate/pyruvate pathway produces NADPH and αKG via 
NADP
+
-dependent isocitrate dehydrogenase (ICDc).
37
  When these pathways are inhibited, there 
is a significant reduction in pyruvate cycling and GSIS.
46 
In the isocitrate/pyruvate pathway, oxaloacetate is converted to citrate via citrate 
synthase, which is then translocated to the cytosol by the citrate isocitrate carrier (CIC) and 
isomerized to isocitrate.
3745,46
 Once in the cytosol, isocitrate produces αKG and NADPH via 
ICDc. αKG can then re-enter the mitochondrial matrix via the 2-oxoglutarate carrier (OGC) to 
stimulate production of TCA cycle intermediates.
37,45,46
 Cytosolic αKG is a β-cell secretagogue 
but the mechanism remains inconclusive.
37 
αKG is a co-substrate for the enzyme prolyl 4-








Figure 1.2: Pyruvate/isocitrate pathway. 
A schematic representation of the pyruvate/isocitrate pathway is shown above.  PC converts 
pyruvate to oxaloacetate which enters the TCA cycle.  Oxaloacetate produces citrate via citrate 
synthase and citrate is translocated to the cytosol via CIC.  In the cytosol, citrate is isomerized to 
isocitrate which produces NADPH and αKG via ICDc.  αKG may re-enter the TCA cycle in the 
mitochondria via 2-OGC but may also act as a co-substrate for PHD to regulate GSIS. 
1.3 Prolyl 4-hydroxylases 
1.3.1 PHD isoenzymes  
There are three isoforms of prolyl 4-hydroxylases (PHD): PHD1, PHD2 and PHD3.  
Other names for the PHD enzymes include Egl nine homolog (Egln), as well as, hypoxia 
inducible factor prolyl 4-hydroxylases (HIF-P4H).
49-53
 Previously described PHDs are 
responsible for altering collagen for exocytosis .
54
 Type I and type II collagen PHDs regulate 
collagen formation and are localized in the ER.
55
 Bruick and colleagues (2001) hypothesized that 




hydroxylating proline residues on hypoxia inducible factor α (HIFα).  HIFα is localized in the 




In humans, PHD1, PHD2 and PHD3 are composed of 407, 426 and 239 amino acids, 
respectively.
49,52
 A transmembrane PHD (PHD-TM) has also been described that consists of a 
502 polypeptide located in the ER with the catalytic domain within the lumen between residues 
59 and 82.
49
 At the amino acid level, PHD1, PHD2, and PHD3 are 42-59% identical to each 
other.
49
 These isoenzymes contain the hydroxylase domain at the C-terminal end, with 55% 
identity.
52




A key difference between PHD1-3 includes different subcellular localizations.  PHD1 
was found to be exclusively expressed in the nucleus; PHD2 mainly expressed in the cytosol and 
PHD3 expressed in almost equal proportions in the cytosol and nucleus.
56
 Another study 
determined all PHDs to be expressed mainly in the cytosol in a wide variety of human tissues, 
including both islets and acinar tissue of the pancreas with PHD3 also expressed in the nucleus.
57
 
PHD2 is expressed in many tissues and cell lines studied, whereas the highest mRNA levels of 
PHD1 and PHD3 were found in the placenta and heart, respectively.
49
 PHD-TM mRNA levels 
were highest in the human brain and pancreas.
58 
PHDs are part of the 2-oxoglutarate dioxygenase superfamily and require molecular 
oxygen and αKG as co-substrates, and Fe
2+
 and ascorbate as cofactors.
49,51-53,59,60
 The catalytic 
site for all dioxygenases is located in a double-stranded β-helix jelly-roll core.
49
 Originally, it 
was determined that PHDs have a Km value for oxygen between 230 and 250µM but is now 
suggested to be approximately 100µM.
51-53




required for the half-maximal catalytic rate, is significantly higher than required in tissues, 
making molecular oxygen necessary for PHD activity.
51-53
 One oxygen atom contributes to the 
oxidative decarboxylation of αKG generating succinate and CO2 and the second oxygen atom 
contributes to the hydroxylation of proline.
53
 αKG is an electron donor that is oxidized to 
succinate.  Succinate and fumarate, substrates in the TCA cycle, inhibit PHD activity via 
competitive inhibition.
53,59,60
 Fumarate and succinate inhibit all PHD isoenzymes with fumarate 
having a Ki value, the concentration for half maximal inhibition, of 50-80µM and succinate 
having a Ki value of 350-460µM.
60
 The use of iron chelators that competitively inhibit Fe
2+
 that 







 binding site is contained in residues H313, D315 and H374 in human 
PHD2.
49
 In mice, the Fe
2+
 binding site is contained in residues H271 and D273 for PHD1, H290 
and D292 for PHD2 and H135 and D137 for PHD3.
62
  Ascorbate ensures maximal catalytic 
activity and has been reported to reduce Fe
3+





The canonical pathway for PHD is through the regulation of HIFα in the hypoxia response 
pathway. 
 
1.3.2 Role of PHD in the hypoxia response pathway 
PHD’s ability to regulate HIFα in the hypoxia response pathway, an adaptive pathway for 
temporary cell survival when oxygen levels are insufficient, has been well documented.
49,63
 
Human HIFα consists of three isoforms, HIF1α, HIF2α and HIF3α.
49,53,64
  HIF contains an 
unstable α subunit and a stable β subunit and is the main regulator for oxygen homeostasis.
51,53,59
  
PHD2 is the main regulator in the hypoxia response pathway, as conditional knockout (KO) of 






 PHD2 is preferential to HIF1α compared to HIF2α, whereas the opposite is true 
for PHD3.
49
 PHDs hydroxylate proline residues at Pro-402 and Pro-564 in –Leu-X-X-Leu-Ala-
Pro sequences located in the oxygen-dependent degradation domain (ODDD) of HIFα in 
normoxic environments, where there is sufficient oxygen availability.
49,51-53
 Both proline 
residues in HIFα are located on the C-terminal end of the polypeptide.
51,52
 
The hydroxylated proline residues are recognized by the von Hippel-Lindau protein 
(pVHL) E3 ubiquitin ligase complex and targeted for ubiquitination and proteasomal 
degradation.
51-53,59,63-65
 However, under hypoxic conditions, PHD is inhibited and HIFα is 
stabilized HIFα localizes to the nucleus and forms a heterodimer with HIFβ.
49,51-53,59,63
 The 
activated heterodimer binds to hypoxia-response elements (HREs) located in the regulatory 
regions of over 100 genes involved in decreasing oxygen consumption and increasing oxygen 
availability.
53
 These genes include those involved with angiogenesis, such as VEGF; 
erythropoiesis, energy metabolism, apoptosis and cell proliferation.
53,59,63
 In particular, HIFα 
upregulates genes that shunt glucose away from oxidative metabolism in the mitochondria and 
increase glycolysis.
66
   Glucose transporter 1 (GLUT1), lactate dehydrogenase (LDHA) and 
pyruvate dehydrogenase kinase 1 (PDK1), which phosphorylates and inhibits pyruvate 




PHD2 KO mouse models lead to complications including polycythemia, increased ratio 
of red blood cell concentration to blood volume, and congestive heart failure.
64
 Rishi and 
colleagues (2015) performed femoral artery ligations in PHD1 and PHD3 double KO mice.  
They determined that PHD1 and PHD3 double KO mice displayed increased VEGF levels and 
improved blood flow.
50




PHD2 KO mice lead to overexpression of erythropoietin (EPO) resulting in polycythemia, but 
PHD1 and PHD3 double KO mice also led to polycythemia to a lesser extent.  Hyperinsulinemia 
in T2D creates a hypoxic microenvironment, stabilizing HIFα to upregulate genes inducing 
oxidative stress and proinflammatory cytokines, resulting in insulin resistance.
68
 There is 
evidence that the hypoxia response pathway plays a role in the pathogenesis of T2D.  
 
 
Figure 1.3: Hypoxia response pathway. 
A schematic representation of the regulation of HIFα by PHD is shown above.  PHDs 
hydroxylate proline residues on HIFα in normoxic conditions.  Prolyl hydroxylated HIFα is 
recognized and targeted by pVHL for degradation.  In hypoxic conditions, HIFα localizes to the 
nucleus and forms a heterodimer with transcription factor HIFβ.  HIFα/HIFβ binds to HREs on 
DNA to upregulate genes involved in increasing oxygen availability and decreasing oxygen 




1.3.3 Role of the hypoxia response pathway in T2D 
There is conflicting evidence regarding the specific roles of the hypoxia response 
pathway in β-cell metabolism, function and development.  Heinis and colleagues (2010) cultured 
rat embryonic β-cells to determine the role of oxygen tension in β-cell differentiation.  When rat 
embryonic β-cells were exposed to hypoxia, HIF1α was stabilized and neurogenin 3 (Ngn3) was 
reduced.
69
 Ngn3 is a transcription factor that is expressed in endocrine progenitor cells during 
embryogenesis and induces β-cell differentiation.
69
 Embryonic β-cells exposed to hypoxia or 
treated with dimethyloxalylglycine (DMOG), a PHD inhibitor, increased HIF1α expression and 
decreased β-cell differentiation.
69
 In a subsequent study, Heinis and colleagues (2012) 
demonstrated that Ngn3 and, therefore, β-cell development was decreased in pVHL depleted 
embryonic islets at E13.5.  It was found that increased HIF1α resulted in decreased β-cell 
differentiation, potentially due to decreased ATP levels when HIF1α is upregulated.
70
 
MIN6 cells, a mouse-derived β-cell line, and primary mouse islets display cellular 
hypoxia when stimulated with high glucose.
71
 Glucose leads to a significant increase in oxygen 
consumption and consequent β-cell hypoxia.
71
 Mild hypoxia during increased insulin secretion 
leads to HIF1α upregulation, causing a shift to anaerobic metabolism to alleviate the high oxygen 
demand.
71
 Hypoxia, upregulated by increased oxygen consumption during GSIS, is exacerbated 
when oxygen availability is compromised.
71
 Sato and colleagues (2011) determined oxygen 
availability to be impaired in both C57BL/6J mice on a HFD and leptin-deficient (ob/ob) mice.  
This was associated with defective microcirculation and blood supply that is seen in T2D.
71
 
Inducing HIF1α via hypoxia would perhaps reduce insulin secretion but also play a protective 






Similarly, INS-1 832/2 glucose unresponsive cells showed increased HIF1α and 
anaerobic metabolism compared to INS-1 832/13 glucose responsive cells.
73
 Spegel and 
colleagues (2011) observed LDHA expression in glucose unresponsive cells, which was not 
expressed in 832/13 glucose responsive cells.  Higher HIF1α protein levels were associated with 
impaired GSIS.
73
 Another study demonstrated that hypoxia was correlated with a 23% decrease 
in insulin content and a 35% decrease in insulin biosynthesis in primary rat islets.
74
 However, 
when primary islets were exposed to diazoxide, a KATP channel activator, prior to hypoxia the 
negative effects of hypoxia were counteracted and β-cell death was decreased.
74
 Preconditioning 
with diazoxide opens KATP channels and inhibits Ca
2+
 influx, reducing basal glucose-stimulated 
mitochondrial metabolism.
72,74
 Preconditioning altered basal mitochondrial metabolism and 
upregulated target genes of HIF1α prior to being exposed to hypoxia, possibly having protective 
effects.
74 
In contrast, a study using β-cell specific HIF1α KO mice determined that HIF1α is 
essential for β-cell function.
75
 Cheng and colleagues (2010) observed that mitochondrial ATP 
production was significantly reduced in HIF1α KO mice.  As well, this decrease in ATP 
production resulted in impaired glucose tolerance and β-cell dysfunction.
75
 Iron chelators, 
deferoxamine (DFO) and deferasirox (DFS), were used to inhibit PHD, stabilizing HIFα and 
significantly improving glucose tolerance and insulin secretion in wild type (WT) mice on a 
HFD.
75
 HIF1α displayed a dose-response relationship with β-cell function and an increase in 
glucose transporters was observed with iron chelators.
75
 A modest increase in HIF1α appeared to 







Chronic hyperglycemia in diabetic patients may in part, regulate the hypoxia response 
pathway via HIF1α.  Sergiu-Bogdan and colleagues (2004) demonstrated that the protective 
effects of HIF1α are impaired by hyperglycemia using human primary dermal fibroblasts and 
endothelial cells.  These observations were reproduced in vivo using biopsies of diabetic chronic 
foot ulcers displaying both hypoxia and hyperglycemia compared to chronic venous ulcers, 
which display a similar hypoxic environment.
76
 HIF1α protein levels were lower in diabetic 
chronic foot ulcers compared to control chronic venous ulcers.
76
 However, the data presented 
may be more relevant to treating the complications that arise from T2D, as the interaction 
between hyperglycemia and hypoxia may be a causal factor in other diabetic complications, 
including retinopathy, neuropathy and kidney disease.
76
 These observations may not be pertinent, 
specifically in the regulation of insulin secretion but rather the global effects of hyperglycemia 
seen in diabetic patients. 
Rodent models have been used to study the role of hypoxia in β-cell GSIS.  PHD 
hypomorph mice, expressing reduced amounts of whole body PHD2 mRNA, were fed a chow or 
HFD.
77
   PHD2 hypomorph mice on both diets had less adipose tissue, smaller adipocytes and 
decreased adipose tissue inflammation resulting in improved glucose tolerance and insulin 
sensitivity.
78
 PHD2 hypomorph mice also displayed increased HIF1α stabilization and 
upregulation of HIF1α target genes, involving glucose transporters and glycolytic enzymes.
78
 
These results were replicated with oral administration of the PHD2 inhibitor FG-4497 in WT 
mice on both diets.
78
 
Taniguchi and colleagues (2013) explored the effects of HIFα on insulin sensitivity using 
hepatic specific PHD3fl/fl mouse.  PHD3fl/fl hepatocytes were infected with an adenovirus 






  Acute hepatic PHD3 knockdown resulted in HIF2α stabilization and improved 
glucose tolerance and insulin sensitivity.
79
 The same results were shown in hepatic specific 
PHD3 KO mice.
79
 This resulted in a 30% decrease in blood glucose levels, as well as a 50% 
decrease in plasma insulin levels.
79
 HIF2α stimulated insulin receptor substrate 2 (IRS2), which 
is necessary for insulin sensitivity.
79
 Interestingly, additional KO of other PHD isoforms led to a 




There are several models used to demonstrate the role of the hypoxia response pathway in 
T2D and specifically β-cell function, including HIFα, pVHL and PHD KO animal models.  
However, in humans, T2D is associated with severe hypoxia, as excessive glucose from nutrient 
overload places a high demand on the mitochondria and oxidative phosphorylation, leading to 
decreased ATP production in the β-cell.
71
 HIFα is also thought to be associated with glucose 
intolerance and insulin insensitivity in β-cells but may have beneficial effects with diabetic 
complications.
76
 It is plausible that HIFα is beneficial at low levels but could lead to toxicity if 
overexpressed.
75
 PHDs are the main regulators of HIFα , however, PHDs also regulate non-HIFα 
targets; with PHD3 having the widest range of targets.
80
 PHD has been shown to prolyl 
hydroxylate other proteins that may be involved in regulating insulin secretion.  
 
1.3.4 Other targets of PHDs 
PHDs prolyl hydroxylate other proteins apart from HIFα.  Particularly, PHD3 is thought 
to play a significant role in apoptosis and tumor development.
81
 Growing tumors have poor 
vasculature leading to decreased oxygen availability, which triggers the hypoxia response 
pathway as a means of temporary cell survival.
81




cancer such as pancreatic, colon and metastatic melanoma.
82
 PHD3 regulates cell proliferation, 
differentiation, and migration and therefore, may play a role in metastatic cancers.
82,83
  
 Actin filaments are required for cell motility and dysregulation of actin is associated with 
cancer development and metastasis.
82
 Luo and colleagues (2014) demonstrate that PHD3 is a 
negative regulator of F-actin, which inhibits metastasis via hydroxylation on proline residues -
307 and -322.  Inhibition of F-actin production led to decreased cell migration and, therefore, 
metastasis.
82
 Paired box 2 (Pax2) is a transcription factor that regulates cell differentiation, 
proliferation, migration, and survival.
84
  Pax2 is expressed in a variety of cancers including 
leukemia, breast, prostate, kidney, and bladder.
84
  PHD3 was found to hydroxylate and target 
Pax2 for degradation post transcriptionally; however, the mechanism remains unclear.
84
  
Sprouty homolog 2 (SPRY2) inhibits cell surface receptors tyrosine kinases, which 
regulate cell proliferation and migration.
83
 Anderson and colleagues (2011) showed that PHD3 
has a stronger interaction with SPRY2 proteins compared to PHD1 and PHD2 through 
immunoblot analysis in HeLa cells.  PHDs interact with SPRY2, inhibiting proliferation and 
migration.
83
 Receptor tyrosine kinase, c-kit plays a role in β-cell maturation and function and 
islet vascularization.
85 
β-cell specific mutation of c-kit resulted in impaired vasculature and β-cell 
function whereas, overexpression in mice significantly improved islet vasculature and β-cell 
function.
85 
PHD3 regulation of SPRY2 elucidate PHD3 as a potential target for the treatment of 
cancer but further research is warranted to investigate whether regulation of these proteins by 
PHD plays a role in β-cell function.  
Activating transcription factor 4 (ATF4) is a regulator of the unfolded protein response, 
determining cell fate.
65
 Koditz and colleagues (2007) showed that PHD3 interacts with the 




DMOG and incubation in 1% oxygen induced ATF4 activity in HeLa cells.
65
 More recently, it 
was shown that ATF4 interacts with PHD1.
86
 PHD1 positively regulated ATF4 in HeLa and 
HEK293T cells, contrary to PHD3.
86
 Immunoprecipitation experiments, where proline residues 
were mutated to alanine, did not affect the interaction of PHD1 or PHD3 with ATF4, suggesting 
that PHD1 and PHD3 do not regulate ATF4 via prolyl hydroxylation.
85
 ATF4 induced 4E-BP1 in 
MIN6 β-cells and primary mouse islets, promoting β-cell survival under ER stress.
87
 4E-BP1 KO 
mice displayed increased ER stress-induced β-cell apoptosis.
87
 PHD interacts with ATF4 in 
cancer cell lines but PHD could potentially interact with ATF4 in β-cells to regulate ER stress 
induced-apoptosis.   
β2-adrenergic receptors (β2AR) are G-protein coupled receptors that regulate receptor 
homeostasis and play a role in cardiovascular disease and pulmonary function.
88
 Hypoxia present 
in patients with heart failure and asthma, stabilizes β2AR and increases catecholamine release.
88
 
This adaptation works to increase cardiac output and peripheral vasodilation to increase oxygen 
availability.
88
 Xie and colleagues (2009) found that siRNA inhibition of PHD3 increased β2AR 
and PHD3 deficient mice displayed increased blood pressure and heart contractility via prolyl 
hydroxylation of β2AR at proline residues -382 and -395.  PHD targets proteins that are involved 
in a variety of cancers and cardiovascular disease, for which T2D is a major risk factor.  PHD 
also targets glycolytic enzymes that alter glucose metabolism and could potentially play a role in 
insulin secretion. 
 
1.3.5 The role of PHD in altering glucose metabolism 
The hypoxia response pathway is an adaptation for temporary cell survival and works to 




hydroxylated via PHD are recognized by pVHL ubiquitin E3 ligase complex and targeted for 
degradation.  pVHL plays a role in oxygen sensing and energy homeostasis.
89
 Vhlh gene KO, the 
gene encoding pVHL, in β-cells of adult mice using the Cre-lox system resulted in β-cell 
dysfunction, impaired glucose tolerance and reduced GSIS in vivo.
89
 Interestingly, insulin 
secretion was normal compared to WT controls at basal conditions but when glucose stimulus 
was increased, insulin secretion was impaired in vivo.
89 
PDH catalyzes the conversion of pyruvate to acetyl-CoA, which enters the TCA cycle for 
ATP production.
90
 PDH is composed of E1α, E1β, E2 and E3 subunits.
90
 PDH activity is 
determined by phosphorylation and dephosphorylation via PDK1, where PDK1 is upregulated in 
hypoxic environments.
90
 PDK1 inhibits PDH by phosphorylating the E1α subunit, decreasing 
acetyl-CoA production and oxidative metabolism.
90
 Kikuchi and colleagues (2014) determined 
that PHD3 KO mouse embryonic fibroblasts (MEFs) and PHD3-depleted MCF7 breast cancer 
cells showed decreased PDH function via immunoprecipitation and western blot analysis PHD3 
KO MEFs were resistant to cell death during prolonged hypoxia.
90 
PHD3 was shown to interact 




 PHD3 has also been shown to interact with pyruvate kinase M2 (PKM2), which catalyzes 
the final reaction in glycolysis, producing pyruvate and ATP.
91
  PHD3 acts as a coactivator by 
binding to PKM2 to enhance PKM2’s interaction with HIFα, stabilizing HIFα and increasing 
GLUT1, lactate dehydrogenase A (LDHA) and PDK1.
91
 These proteins enhance glucose uptake, 
lactate production, and inhibit oxidative metabolism, respectively, resulting in the Warburg 
effect.
91
  The Warburg effect is a metabolic shift towards glycolysis to reduce oxygen utilization 
in many types of cancer cells.
91 




HEK293T cells via retrovirus or lentivirus resulted in reduced glucose uptake and lactate 
production, and increased oxygen consumption.
91
  It was determined using in vitro hydroxylation 
assays that PHD3 hydroxylates proline residues at positions -403 and -408 on PKM2.
91 
 Some cancers, such as acute myeloid leukemia rely on fatty acid oxidation (FAO).
92
 
PHD3 was shown to inhibit FAO by hydroxylating proline residues at position -450 and 
activating acetyl-CoA carboxylase 2 (ACC2) in 293T cells.
92
 ACC2 inhibits carnitine palmitoyl 
transferase 1 (CPT1), thereby reducing long-chain fatty acid translocation from the cytosol into 
the mitochondria for oxidative metabolism.
92
 Repression of FAO by PHD3 resulted in increased 
apoptosis and PHD3 overexpression resulted in a 50% reduction of FAO in cells.
92
  
 Cell lines and animal models using siRNA inhibition and pharmacological inhibitors 
including broad and specific inhibitors have been used to study the role of PHD in a variety of 
pathways.  A well-established PHD inhibitor used in the experiments that are presented in this 
thesis is the synthetic αKG analogue, DMOG, to investigate the role of PHD in GSIS.   
1.4 Pharmacological inhibitors of PHDs 
1.4.1 Dimethyloxalylglycine (DMOG) 
DMOG is a competitive inhibitor of all PHD isoforms and other members of the 2-
oxoglutarate dioxygenase superfamily.
93,94
 DMOG is a synthetic amide analogue of αKG and
 
is 
able to penetrate cell membranes where it is then converted to N-oxalylglycine (NOG) via 
carboxylesterases.
93,94
 DMOG also increases the amount of substrate that binds to PHDs.
95
  
Zhdanov and colleagues (2015) measured ATP production in HCT116 cancer cells 
treated with DMOG and deprived of glucose.  There was a significant decrease in ATP 
concentration in cells deprived of glucose 30 minutes after DMOG treatment and ATP levels 






results reveal that DMOG is fast-acting and may alter metabolism faster than HIF-dependent 
mechanisms.
93 
DMOG has been used to study oxygen-induced retinopathy (OIR).
96,97
  The first phase of 
OIR hyperoxia results from decreased VEGF due to destabilization of HIFα.
96,97
  OIR rats were 
intraperitoneally injected with 200µg/g DMOG causing systemic reduction in PHD, stabilizing 
HIFα.
96,97
  Intraperitoneal injection of 200µg/g was sufficient to upregulate HIFα and provide 
protective effects in hyperoxic OIR rats.
96,97
  Before the discovery of PHD, iron chelators were 
used to induce HIFα expression.  More recently, selective PHD inhibitors have been developed, 
some of which are in clinical trials for end stage renal disease. 
 
Figure 1.4: Comparing αKG and DMOG. 
The chemical structures of the TCA cycle intermediate αKG and the PHD inhibitor DMOG.  





1.4.2 Other inhibitors of PHD 
Other PHD inhibitors include iron chelators and selective PHD inhibitors.
47,94,98
 The iron 
chelator ethyl-3,4-dihydroxybenzoate (EDHB) is a competitive inhibitor of PHD, creating an 
iron deficient environment  resulting in decreased PHD activity.
98
 EDHB also displays a strong 
inhibition towards αKG and ascorbate.
98
  Huang and colleagues (2016) found EDHB reduced 
GSIS in 832/13 cells at 100 and 2000µmol/L but increased GSIS at 200 and 500µmol/L.  EDHB 
reduced the ATP/ADP ratio and TCA cycle intermediates including pyruvate, citrate, fumarate, 
and malate in 832/13 cells, suggesting PHD plays a role in oxidative metabolism.
47
 However, 
EDHB is not as specific as other PHD inhibitors and is suggested to play a negative role in iron 
metabolism.
98
    
FG-4592, also known as Roxadustat, is a hypoxia mimetic and is currently in phase III 
clinical trials for the treatment of anemia and chronic kidney disease via upregulation of 
erythropoietin (EPO) through HIFα stabilization.
99,100
 FG-4592 treated HEK293T cells displayed 
increased GLUT1, hexokinase 2, and LDHA, upregulating glycolysis by 25%.
99
 FG-4592 shunts 
carbon away from aerobic metabolism and towards anaerobic metabolism in both a hypoxic and 
normoxic environment.
99
 FG-4592 may also play a beneficial role in mitochondrial dysfunction 
and a potential treatment option for T2D.
99,100
 Clinical trials using another hypoxia mimetic, 
GSK1278863, reported decreased serum cholesterol levels and improved HDL/LDL lipoprotein 
profiles as side effects.
101 
FG-2216 (IOX3) was used in a phase I clinical trial in 12 end-stage renal disease patients 
who were on dialysis.
102,103
 Oral administration of 20mg/kg body weight FG-2216 increased 
endogenous EPO production.  However, this study lasted 7 days and the long-term effects of FG-
2216 is unknown.
102






and colleagues (2016) assessed the regulation of hypoxia-regulated genes and found that FG-
2216 resulted in a 35% increase in HIFα gene targets, compared to DMOG, which resulted in a 
50% increase in HIFα gene targets.    
IOX2 is a selective PHD2 inhibitor, where the thiazole ring displaces the side chain of 
αKG.
103
 IOX2 has a 400-fold selectivity for PHD2, whereas IOX4 has an 857-fold selectivity for 
PHD2 but is also suggested to be a potent inhibitor of PHD1 and PHD3.
103
 Mice were injected 
with IOX2, IOX4 and DMOG to assess potency.
103
 IOX2 was shown to have the strongest 
induction of HIF1α and HIF2α with DMOG displaying the lowest induction.
103
However, Chan 
and colleagues (2016) concluded that DMOG better represented the hypoxic response compared 
to  selective PHD inhibitors through in vitro hydroxylation assays in MCF-7 cells compared to 
cells incubated in 0.5% oxygen.  HIF1α and HIF2α were significantly upregulated by both 
hypoxia and DMOG and upregulated to a lesser extent by FG-2216 and IOX2.
94 
PHD inhibitors 
have been used in multiple cell lines, rodent models and  human clinical trials to assess the role 
of PHD and HIFα in disease states.  The experiments presented in this thesis focus on exploring 
the role of PHD using  DMOG in primary mouse islets and male C57BL/6J mice, as well as, 
discussing future research exploring the role of PHD in a transgenic mouse model.   
1.5 Animal models 
1.5.1 Cre-lox System 
Another approach to studying the role of specific genes in disease states is to use a 
transgenic mouse model, which can either overexpress or KO a gene of interest.  The Cre-lox 
system is done by homologous recombination in embryonic stem cells and introduces nucleotide 






 These loxP sequences are recognized by the Cre-recombinase (Cre) enzyme, which 
recognizes the loxP sites to generate a KO.
104
  
  Mice that contain loxP sequences around a specific exon within a gene are crossed with 
mice that express Cre under a tissue-specific promotor to allow deletion of the gene in a 
particular tissue.
104
 Previous models used Cre expressed on the rat Ins-2 gene, but Ins-2 is also 
expressed in the hypothalamus in both embryonic and adult mice.
104
 Thorens and colleagues 
(2015) generated mice expressing Cre on the β-cell specific Ins-1 gene.  Mice expressing Cre on 
the eostrogen receptor fusion protein (Cre
ERT2
), in which Cre is activated via tamoxifen 




may be beneficial 
when studying disease states with later onsets, such as T2D.   
 Thorens and colleagues (2015) demonstrated the selectivity of expressing Cre on the Ins-




 mice with Rosa26-eYFP mice to determine tissues 
containing loxP site recombination by immunofluorescence.  Recombination was exclusively in 






 It was concluded that four injections of 







mice can then be crossed with mouse models 
containing loxP sites around an exon within a particular gene, such as PHD, to generate PHD KO 
mice. 
 
1.5.2 PHD transgenic mice 
In the experiments presented in this thesis, transgenic PHD123fl/fl mice and PHD2fl/fl 




around exon 3 for PHD1.
62
 All of the loxP sites are approximately 230 base pairs long and 
located in the intron sequences.
62 
When PHD123fl/fl and PHD2fl/fl mice are crossed with C57BL/6J mice expressing Cre 
recombinase exclusively in pancreatic β-cells, the result is offspring with exon 2 or exon 
3deleted, generating PHD KO mice in β-cells.
62
 These exons contain residues His-271 and Asp-
273 in PHD1, His-290 and Asp-292 in PHD2, and His-135 and Asp-137 in PHD3.
62
 These 
histidine and aspartate residues are required for Fe
2+
 binding, and therefore PHD activity.
62
      
1.6 Rationale 
The complexity of T2D poses a major issue in treatment and management, often leading 
to combinational therapy with adverse effects.  Understanding the mechanisms of pancreatic β-
cell insulin secretion, particularly involvement of KATP channel-independent pathways, is needed 
to develop more effective treatment strategies.  Therefore, our lab studies the role of PHD in 
second-phase insulin secretion utilizing cytosolic αKG as a co-substrate to regulate insulin 
secretion.  Previous studies elucidate the importance of pyruvate cycling through PC to generate 
metabolites, such as αKG, that results in increased GSIS.
105 
Pyruvate enters the mitochondria and undergoes oxidative metabolism to increase insulin 
secretion.  Pancreatic β-cells express abundant PC and PDH and in approximately equal 
proportions.
105-107
 In gluconeogenic tissues, the formation of glucose from non-glucose 
precursors such as the liver, PC plays a major role.
107
 Gluconeogenic enzymes 
phosphoenolpyruvate and fructose-1,6-bisphosphotase are rate-limiting but are not expressed in 
pancreatic β-cells, signifying another role for PC in islets.
107 
 In particular, PC is reduced in β-
cells of T2D rodent models.
105
 siRNA inhibition of PC in 832/13 cells and dispersed rat islets 




intermediate concentrations of oxaloacetate, malate, ATP and NADPH, suggesting that PC is 
required for anaplerosis.
105
 Overexpression of PC led to increased insulin secretion and 




Pyruvate cycling plays a role in stimulating insulin secretion and depends on the transport 
of TCA cycle metabolites to the cytosol.
46
 TCA cycle intermediates including NADPH and αKG 
may function as coupling factors linking glycolysis in the cytosol to cellular respiration in the 
mitochondria leading to increased GSIS.
46,108
 There are three pathways involved in pyruvate 
cycling: the pyruvate/malate pathway, pyruvate/citrate pathway, and pyruvate/isocitrate pathway 
that generate NADPH and αKG, important signaling molecules that are involved in insulin 
secretion.
46
 In the pyruvate/malate pathway, malate is transported to the cytosol by dicarboxylate 
carrier (DIC) and malic enzyme converts malate to pyruvate, producing NADPH.
46,108
 Inhibition 
of DIC resulted in inhibition of the pyruvate/malate shuttle and reduced NADPH and GSIS in 
832/13 cells and primary rat islets.
46
  
The citrate isocitrate carrier (CIC) transports citrate and isocitrate from the mitochondria 
to the cytosol and is involved in the pyruvate/citrate and pyruvate/isocitrate shuttles.
46
 
Pharmacological inhibition of CIC resulted in decreased GSIS in 832/13 cells and primary rat 
islets in first- and second-phase insulin secretion.
109
 As well, overexpression of CIC resulted in 
increased GSIS, demonstrating the importance of cytosolic citrate and isocitrate in insulin 
secretion.
109
 NADP-dependent isocitrate dehydrogenase (ICDc) converts cytosolic isocitrate to 
αKG, producing NADPH as a by-product.
46,110
 Ronnenbaum (2006) and colleagues found that 
siRNA inhibition of ICDc resulted in decreased GSIS in both 832/13 cells and primary rat islets, 




 Using liquid chromatography/mass spectrometry, Lorenz and colleagues (2013) observed 
a transient decrease in αKG after a glucose stimulus but a 3- to 4- fold increase at later time 
points.  The later increase supports the role of αKG in anaplerosis to augment second-phase 
insulin secretion via pyruvate cycling.
112
 Huang and Joseph (2014) revealed that αKG levels did 
not increase until 10 minutes after a glucose load in 832/13 cells and continued to rise through 
the 60 minute period.  These results suggest that αKG is a coupling factor in KATP channel-
independent pathways.
40 
Transportation of αKG from the mitochondria to the cytosol is 
facilitated by the 2-oxoglutarate carrier (OGC).
110
 OGC siRNA knockdown in 832/13 cells and 
primary rat islets revealed significantly reduced GSIS.
110
 Pharmacological inhibition of OGC via 




 αKG plays a role in second-phase insulin secretion but the mechanism remains 
incompletely understood.  Fallon and colleagues (2008) used EDHB in human and rat pancreatic 
islets.  EDHB was found to inhibit PHD by approximately 50% and reduced insulin secretion by 
90%.
48
 It is suggested that αKG translocation to the cytosol is required for insulin secretion by 
serving as a co-substrate for PHDs.
48
 EDHB also inhibited glucose utilization, ATP content and 
TCA cycle intermediates pyruvate, citrate, fumarate and malate.
47
  siRNA inhibition of PHD1, 
PHD2, and PHD3 in 832/13 cells determined that PHD1 and PHD3 knockdown decreased GSIS 
whereas PHD2 did not affect GSIS.
47
  Our lab chose to further explore the role of PHDs in 
pancreatic β-cell insulin secretion using the pharmacological inhibitor DMOG in both INS-1 
832/13 cells and primary mouse islets to study acute effects of PHD inhibition.  We have also 
generated PHD KO transgenic mice to explore both short- and long-term effects of PHD in 





Figure 1.5: TCA cycle intermediate transport carriers. 
CIC transports citrate and isocitrate from the mitochondria to the cytosol.  ICDc converts 
isocitrate to αKG and produces NADPH.  NADPH and αKG may be signaling molecules that 
stimulate insulin secretion.  αKG also acts as a co-substrate for PHD, which may directly 
regulate insulin secretion.  Illustration reproduced courtesy of Dr. Jamie Joseph.  
  









Chapter 2: Objectives and Hypothesis 
2.1 Hypothesis 
 Nutrient-stimulated anaplerosis increases cytosolic αKG, enhancing PHD activity 
resulting in short- and long-term effects on insulin secretion.   
2.2 Objectives 
1. Confirm expression and subcellular localization of PHD1, PHD2, and PHD3 in INS-1 
832/13 cells and primary mouse islets by western blot analysis and immunofluorescence. 
2. Assess the role of PHDs using DMOG in vitro by measuring oxygen consumption rate 
and both static and dynamic insulin secretion. 
3. Assess the role of PHDs using DMOG in vivo by measuring blood glucose levels and 
plasma insulin levels in response to an exogenous glucose load. 















Chapter 3: Methods 
3.1 PHD expression and subcellular localization 
3.1.1 Western blot 
 Protein samples were collected from 832/13 cells and primary mouse islets after an 
insulin secretion assay.  Protease inhibitor cocktail (Sigma, Oakville, ON) was diluted in a 1X 
lysis buffer (diluted in milliQ H2O) (Cell Signaling, Danvers, MA, USA) (1:400) and was added 
to 832/13 cells or a 3X lysis buffer (diluted in milliQ H2O) (Cell Signaling, Danvers, MA, USA)   
was added to isolated islets (120-150 islets/treatment) infected with shGFP, RIP Cre adenovirus 
(Vector Biolabs, Malvern, PA, USA) or no treatment (NT).  832/13 cells were treated with low 
glucose (LG) (2mM) and islets were treated with LG (2mM), high glucose (HG) (16.7mM), LG 
(2mM) + KCl (30mM) + diazoxide (200µM), HG (16.7mM) + KCl (30mM) + diazoxide 
(200µM) or HG (16.7mM) + dimethyl maleate (DMM) (10mM) + dimethyl α-ketoglutarate 
(DMαKG) (10mM).  All treatments were diluted in cell Krebs-Ringer bicarbonate buffer (KRB) 
(KRB stock (4.32mM KCl, 1.20mM MgSO4, 1.5mM KH2PO4), 129mM NaCl, 10mM HEPES, 
5mM HCO3, 3.11mM CaCl2, 0.1% BSA, pH 7.4) or islet KRB (KRB stock (120mM NaCl, 
4.8mM KCl, 2.5mM CaCl2, 1.2mM MgCl2), 5mM HEPES, 24mM HCO3, 0.1% BSA, pH 7.4).  
832/13 cells were scraped and centrifuged at 12,500 rpm for 30 minutes at 4˚C.  Islets were 
incubated on ice for 15 minutes and centrifuged at 12,500 rpm for 30 minutes at 4˚C.  Protein 
concentration for 832/13 cells was determined by a bicinchoninic acid (BCA) protein assay.  
NuPAGE LDS sample buffer (4X) (ThermoFisher Scientific, Carlsbad, CA), NuPAGE reducing 
agent (10X) (ThermoFisher Scientific, Carlsbad, CA) and deionized water were added to 
approximately 20µg of protein from 832/13 cells and total protein for islets (120-150 




Tris SDS polyacrylamide Mini Gel (ThermoFisher Scientific, Carlsbad, CA) with 1X running 
buffer (Life Technologies, Carlsbad, CA) (supplemented with NuPAGE antioxidant 
(ThermoRisher Scientific, Carlsbad, CA)) for 50 minutes with a maximum voltage of 200V.   
A 0.45 µM pore size Invitolon PVDF membrane (Life Technologies, Carlsbad, CA) was 
activated using methanol and protein samples were transferred to a PVDF membrane for 1.5 
hours with a maximum voltage of 30V in 1X transfer buffer (ThermoFisher Scientific, Carlsbad, 
CA) (supplemented with NuPAGE antioxidant (ThermoFisher Scientific, Carlsbad, CA)).  PVDF 
membranes were washed twice for five minutes with tris-buffered saline (TBS) (0.1% tween).  
PVDF membranes were incubated for 30 minutes with superblock blocking buffer 
(ThermoFisher Scientific, Carlsbad, CA).  PVDF membranes were incubated for two hours for 
all primary antibodies and one hour for all secondary antibodies at room temperature with three 
five minute washes in between with TBS (0.1% tween).  The following antibodies were used: 
rabbit Anti-PHD1/prolyl hydroxylase (1:1000) (Abcam, Toronto, ON), rabbit PHD2/Egln1 
Rabbit mAb (1:1000) (Cell Signaling, Danvers, MA), rabbit Anti-PHD3 (1:1000) (Abcam, 
Toronto, ON), Anti Rabbit IgG (1:10000) (Sigma, Oakville, ON), Anti-Mouse IgG (1:10000) 
(Sigma, Oakville, ON) and mouse Monoclonal Anti-γ-Tubulin (1:10000) (Sigma, Oakville, ON).  
Images were detected using Kodak Image Station 4000 MM Pro using 1mL Luminata Crescendo 
Western HRP Substrate (Millipore, Billerica, MA).  Western Blot images were analyzed using 
Imagej (https://imagej.nih.gov/ij/) (Bethesda, MD, USA). 
 
3.1.2 Immunofluorescence  
 Male mouse pancreases were isolated and fixed in Z-fix solution (Anatech, LTD, MI, 




to be mounted on formalin-fixed, paraffin-embedded slides.  Slides were placed in three xylene 
baths for five minutes each.  Slides were then placed in two 100% ethanol baths for five minutes 
each and then 70% ethanol once for five minutes.  Slides were rinsed under running water for 
approximately 30 seconds.  400mL 1X antigen retrieval solution (Dako, Mississauga, ON) was 
microwaved on high for four minutes.  Slides were then placed in the antigen retrieval solution 
and microwaved on high for an additional five minutes.  Slides were cooled for one minute under 
running water.  Slides were blocked with superblock solution (Thermo Scientific, Mississauga, 
ON) for 30 minutes.  
 Rabbit mAb PHD1 (1:100), Rabbit mAb PHD2 (1:50) or Rabbit pAb PHD3 (1:100) 
antibodies were diluted in superblock solution and 1mL of diluted antibody was placed on each 
slide and incubated overnight at 4˚C.  The following morning, slides were washed three times for 
five minutes with PBS.  Alexa Fluor® 647 anti-rabbit IgG secondary antibody (1:500) (Life 
Technologies, OR, USA) was diluted in superblock solution and 1mL of diluted antibody was 
placed on each slide and incubated for two hours at room temperature.  Slides were washed three 
times for five minutes with PBS.  Guinea pig anti-insulin antibody (1:600) (Dako, Mississauga, 
ON) was diluted in superblock and 1mL was added to each slide and incubated for two hours at 
room temperature.  After incubation, slides were washed three times for five minutes with PBS.  
Anti-Guinea Alexa Fluor® 488 secondary antibody (1:500) (Jackson Immunoresearch, PA, 




room temperature.  After incubation, slides were washed three times for five minutes with PBS 
and then rinsed for 30 seconds under running water.  Slides were placed in 50%, 70% and 100% 
ethanol baths for one minute each.  Slides were then placed in three xylene baths for five minutes 
each.  One drop of Prolong Gold (Life Technologies, Mississauga, ON) was added to a cover slip 
and placed on each slide.  Slides were set to dry overnight at room temperature.  
Immunofluorescence was analyzed using a Nikon Eclipse Ti microscope (Mississauga, ON, CA).   
3.2 In vitro experiments 
3.2.1 Oxygen consumption rate (OCR) 
 Oxygen consumption was measured using Seahorse Bioscience XF24 Respiration Assay 
(Lexington, MA, USA).  832/13 cells were plated at a concentration of 100,000 cells per well 
and islets were plated at a concentration of 45 islets per well.  Cells were plated on a XF24 V7 
culture microplate and grown for five days.  Islets were plated on a V17 TC-treated XF24 islet 
capture microplate the following day after islet isolation.  Each well of the utility plate in the 
XF24 extracellular flux assay kit was filled with 1mL of calibrant solution and hydrated 
overnight (37˚C, no CO2).  Cell media (RPMI-1640 supplemented with 50mL FBS, 11mL 50X 
INS (200mM glutamine, 100mM Na pyruvate, 35.2µL 2-mercaptoethanol) and 5mL P/S 
antibiotic) or islet growth media (RPMI-1640 supplemented with 0.5mL of HEPES (1M, pH 
7.4), 5mL FBS, 0.1mL P/S/F (10000U/mL penicillin G sodium, 10000µg/mL of streptomycin 
sulfate, 25µg/mL of amphotericin B as fungizone) and 0.55mL 200mM glutamine) was replaced 
with LG (2mM) KRB for two one hour washes for 832/13 cells and two 30 minute washes for 
islets (37˚C, 5% CO2).  After two washes, wells were replaced with fresh LG (2mM) KRB.  Port 




B, C and D contained 200µM, 500µM, and 1000µM DMOG diluted in HG (16.7mM) KRB, 
respectively for 832/13 cells and 1mM, 5mM, and 10mM DMOG diluted in HG (16.7mM) KRB, 
respectively for islets.  Port B in all rows contained 10µM oligomycin for 832/13 cells and 20µM 
oligomycin for islets, port C in all rows contained 50µM 2,4-dinitrophenol (DNP) + 20mM 
sodium pyruvate for 832/13 cells and 100µM DNP + 5mM DMM + 5mM DMαKG for islets, 
and port D in all rows contained 5µM of rotenone + 5µM myxothiazol for 832/13 cells and 
10µM rotenone + 10µM myxothiazol for islets.  75µL of all drugs were added to each port in the 
cartridge sensor and all drugs were diluted in HG (16.7mM) KRB.  The utility plate with the 
cartridge sensor was placed in the instrument tray and calibrated.  The utility plate containing the 
calibrant solution was replaced with the cell or islet plate after calibration.  The mix-wait-
measure cycles were three minutes, two minutes, and three minutes, with at least three cycles for 
each injection.  
Spare respiratory capacity was calculated by subtracting basal oxygen consumption rate 
(OCR) from pyruvate + DNP or DNP + DMM + DMαKG OCR values.  Proton leak was 
calculated by subtracting rotenone + myxothiazol OCR values from oligomycin OCR values.  
ATP turnover was calculated by subtracting oligomycin OCR values from basal OCR values.  






Figure 3.1: Seahorse Bioscience XF24 Respiration Assay sensor cartridge. 
 Drugs were loaded into respective ports in wells containing 832/13 cells or islets.  Port A row A 
contained 75µL of HG (16.7mM) KRB, Port A rows B, C and D contained 75µL of 200µM, 
500µM, and 1000µM DMOG diluted in HG (16.7mM) KRB, respectively for 832/13 cells and 
1mM, 5mM, and 10mM diluted in HG (16.7mM) KRB, respectively for islets.  Port B in all rows 
contained 75µL of oligomycin, port C in all rows contained 75µL of pyruvate + DNP for 832/13 
cells and DNP + DMM + DMαKG for islets and port D in all rows contained 75µL of rotenone + 
myxothiazol.  All ports in wells A1, B4, C3, and D5 contained 75µL of deionized water as 
blanks.  Illustration reproduced courtesy of Dr. Jamie Joseph. 
 
3.2.2 Islet isolation 
 Pancreatic islets were isolated from C57BL/6J male mice aged 10-14 weeks (Jackson 
Laboratories) or PHD123fl/fl male mice aged 10-14 weeks (University of Connecticut, USA).  
Mice were anesthetized with 100mg/kg body weight pentobarbital (54.7mg/mL solution, CEVA 
Sante Animale).  Incisions were made in a T-shape form and the common bile duct was located. 
The bile duct was first sutured distally, where the bile duct meets the duodenum.  A second 




approximately 1/3 below the proximal suture.  A 27 ¾ G needle attached to a syringe containing 
digestion media (Hanks dissociation buffer supplemented with 10mM HEPES, 1.28µg/mL 
DNase I, and 0.4 wu units/mL of Liberase TL Research Grade (Roche)) was used to cannulate 
the common bile duct.  The pancreas was perfused with approximately 2-3mL of digestion 
media.  A blunt dissection was performed to remove surrounding tissue and to isolate the 
pancreas.  After islets were digested in a water bath for 30 minutes at 37˚C, islets were washed 
three times to remove debris and prevent DNA contamination.  Islets were placed in a petri dish 
and picked under a stereomicroscope and cultured in 3mL islet growth media (RPMI-1640 
supplemented with 10mM HEPES, 10% FBS, 0.1mL P/S/F and 2.2mM glutamine) in a 6-well 
plate until the day of assay (37˚C, 5% CO2). 
 Approximately 150 islets per treatment from PHD123fl/fl male mice were picked into a 
6-well plate containing 2mL of islet growth media.  Islets were infected with a shGFP control 
virus or a RIP Cre adenovirus at a concentration of 2µL/mL compared to NT.  20mM glucose 
was added to all treatments and incubated for 18 hours overnight.  The following day, the islets 
were washed with PBS and fresh islet growth media was added to each treatment.  GFP and RFP 
were analyzed using a Nikon Eclipse Ti microscope on day two and three.  On day four, an 
insulin secretion assay was performed and insulin concentrations were measured by a 
radioimmunoassay (RIA) (Millipore, Toronto, ON). 
 
3.2.3 Islet dispersion 
 Approximately 120-150 islets were collected into each 1.5mL Eppendorf tube.  Islets 
settled to the bottom and the media was removed.  Islets were washed with 1mL of PBS.  Islets 




each tube and islets were transferred to a 48-well plate.  The 48-well plate was incubated (37˚C, 
5% CO2) for two minutes at a time and checked for disintegration under a stereomicroscope and 
pipetted up and down to mix.  The plate was incubated for a total of 10 minutes.  
 Once 70% of islets were dispersed in each well, 500µL of ice cold islet growth media 
was added to each well.  Each well containing dispersed islets was transferred to a 1.5mL tube 
and centrifuged at 3,000 rpm for two minutes at 4˚C.  A pellet was formed and the supernatant 
was removed.  Another 500µL of ice cold islet growth media was added and the pellet was re-
suspended.  Dispersed islets were centrifuged at 3,000 rpm for two minutes at 4˚C.  The 
supernatant was removed and the pellet was re-suspended in 1mL ice cold islet growth media.  
500µL of dispersed islets was added to each well in a 48-well plate.  The media was changed 
every day until an insulin secretion assay was performed.   
 
3.2.4 Glucose-stimulated insulin secretion (GSIS) assay  
 Approximately 48 hours after islet dispersion, wells were washed twice with 200µL LG 
(2mM) KRB.  The plate was rocked back and forth and inverted to remove LG (2mM) KRB.  
Wells were incubated (37˚C, 5% CO2) twice with LG (2mM) KRB for 30 minutes and washed 
with 200µL LG (2mM) KRB in between incubations.  
 After two washes, wells were treated with LG (2mM) KRB, HG (16.7mM) KRB, LG 
(2mM) KRB + DMOG (5mM) or HG (16.7mM) KRB + DMOG (5mM).  Wells containing 
treatments were incubated (37˚C, 5% CO2) for one hour.  After one hour incubation, 150µL of 
dispersed islets were collected and transferred to a 96-well plate.  Samples were stored at        -




 Islets infected with shGFP, RIP Cre adenovirus or NT were washed twice with LG 
(2mM) KRB and incubated twice for 30 minutes (37˚C, 5% CO2) with LG (2mM) KRB.  After 
incubations, islets were washed once with LG (2mM) KRB and incubated for one hour in the 
following treatments: LG (2mM) KRB, HG (16.7mM) KRB, LG (2mM) KRB + KCl (30mM) + 
diazoxide (200µM), HG (16.7mM) KRB + KCl (30mM) + diazoxide (200µM) and HG 
(16.7mM) KRB + DMM (10mM) + DMαKG (10mM) with 30 islets per treatment.  
 
3.2.5 Islet perifusion 
 Islet perifusion was performed the following day after islet isolation using the Biorep 
Perifusion System (Biorep Teachnologies, FL, USA).  Islets were incubated (37˚C, 5% CO2) 
overnight.  The peristalic pump was set up, connecting the solutions to the main pump and the 
main pump to the chambers.  The chambers were set up and a fiberglass filter was placed on the 
bottom of each chamber.  Chambers were filled with approximately 275µL of LG (2mM) KRB.  
25 islets were washed and picked into each chamber.  The solutions were delivered by the main 
pump to the islets contained within the perifusion chambers.  The Perifusion System was primed 
to prevent air bubbles from forming within the tubes.  The Perifusion System was then heated to 
37˚C.  
 All treatments were perfused at a flow rate of 300µL/minute.  Islets within all chambers 
were stimulated with LG (2mM) KRB for 70 minutes total, baseline measurements of insulin 
secretion were obtained in the first 60 minutes and samples were collected for the latter 10 
minutes.  Islets within the chambers were then stimulated with HG (16.7mM) KRB or HG 
(16.7mM) KRB + DMOG (5mM) for 40 minutes.  Islets within all chambers were stimulated 




 Insulin samples (300µL) were collected in a 96-well plate and stored at -20˚C.  The 
fiberglass filter containing islets in each chamber was collected in a 1.5mL tube.  100µL of acid 
ethanol (150 ethanol:47 H2O:3 HCl) was added to each tube and samples were stored overnight 
at 4˚C and then stored at -20˚C until the day of assay.  All insulin samples were measured by an 
RIA.   
 
3.2.6 Radioimmunoassay (RIA)  
 Insulin samples from islet insulin secretion and islet perifusion assays were measured 
using a Sensitive Rat Insulin Radioimmunoassay Kit (RIA) (Millipore, Toronto, ON).  The RIA 
kit was able to cross react with insulin samples secreted from mouse islets.  
125
I-insulin sensitive 
tracer, a radioactive tracer, and a rat insulin antibody were added to each sample in equal 
amounts.  The 
125
I-insulin tracer and the unlabeled insulin samples compete for binding sites on 
the rat insulin antibody.  Samples containing the rat insulin antibody and 
125
I-insulin tracer were 
centrifuged at 3,000 g for 20 minutes at 4˚C and decanted.  The bound 
125
I-insulin tracer to 
unlabeled antigen ratio in the supernatant was measured using a gamma counter (PerkinElmer, 
Waltham, MA, USA).  The less 
125
I-insulin tracer present in the supernatant, the more insulin 
was present in the sample.   
3.3 In vivo experiments 
3.3.1 Intraperitoneal glucose tolerance tests (ipGTT)  
 C57BL/6J male mice aged 10-14 weeks were fasted for 16-17 hours prior to a glucose 
challenge.  Mice were injected with 200µg/g DMOG or PBS control intraperitoneally 30 minutes 
prior to a glucose challenge.  All mice were injected with 1.5g glucose/kg body weight 






 Next, Bayer, Mississauga, ON, CA) at baseline, 10, 20, 30, 60, 90 and 120 
minutes after an exogenous glucose load.  Blood samples were collected at baseline, 10 and 30 
minutes.  Samples were centrifuged at 8,000 g for 10 minutes.  Plasma was isolated and stored at 
-20˚C until day of assay. Plasma insulin was measured using an enzyme-linked immunosorbent 
assay (ELISA). 
 
3.3.2 Enzyme-linked immunosorbent assay (ELISA)  
 Plasma insulin levels from ipGTTs were measured using a Rat/Mouse Insulin ELISA Kit 
(Millipore, Toronto, ON).  Plasma insulin levels were added to a microtiter plate coated with 
mouse monoclonal anti-rat insulin antibodies.  A rat/mouse insulin detection antibody (pre-
titered biotinylated anti-insulin antibody) was added to the unknown samples to immobilize 
plasma insulin.  To develop the plate, enzyme substrate 3,3’,5,5’-tetramethylbenzidine was 
added to the samples.  A stop solution (0.3M HCl) was added to terminate the colour 
development and the colour change was measured spectrophotometrically at an absorbance of 
450 nm.   
 
3.3.3 Genotyping and development of a KO mouse model 
 Transgenic mouse lines PHD123fl/fl and PHD2fl/fl were purchased from Dr. Guo-Hua 





, and male C57BL/6J mice were purchased from Jackson 





models were previously described.
62,105
 DNA was collected from ear clippings and a DNA 




Mississauga, ON).  DNA was amplified by polymerase chain reaction (PCR) using 2x Phusion 
Master Mix with GC or HF buffer (Thermo Scientific, Mississauga, ON), 1µM of each primer 
and corrected to a final volume of 20µL.  The following primers were used: PHD1 forward: 5’-
TGA GAC CAG GCA GAG GGA GTT-3’, PHD1 reverse: 5’-GGA GCT GGA GTT CTA GGT 
CAG GTT-3’, PHD2 forward: 5’-GTG TAC CTC AAC CTC CGC TC-3’, PHD2 reverse: 5’-
AGG GGA TTT GTA GTT GGC CG-3’, PHD3 forward: 5’-GCT CGG AGA ACT TGA CAC 
GA-3’, PHD3 reverse: 5’-TGA CCT CGT AGG GCT CAG AT-3’, Ins-1 Cre common: 5’-GGA 
AGC AGA ATT CCA GAT ACT TG-3’, Ins-1 Cre WT: 5’-GTC AAA CAG CAT CTT TGT 
GGT C-3’, Ins-1 Cre mutant: 5’-GCT GGA AGA TGG CGA TTA CG-3’.  Primers were 
obtained from Integrated DNA Technologies (Coralville, IA, USA) or Jackson Laboratories (Bar 
Harbor, ME, USA).  The PCR products were separated by gel electrophoresis on a 1.2% agarose 
gel.  The following band lengths were determined: WT PHD1: 500 base pairs (bp), floxedPHD1: 
600 bp, WT PHD2: 1440 bp, floxedPHD2: 1900 bp, WT PHD3: 1070 bp, floxedPHD3: 1550 bp, 
WT Cre: 488 bp, and mutant Cre: 675 bp.  
3.4 Protein identification 
3.4.1 Protein isolation 
 Cells were plated in a 12-well plate at a concentration of 750,000 cells per well and 
grown to 100% confluency for five days.  Wells were incubated (37˚C, 5% CO2) twice with LG 
(2mM) KRB for one hour.  After incubations, wells were treated with 500µL of cell media, LG 
(2mM) KRB, HG (16.7mM) KRB, 500µM DMOG, 10mM DMαKG, 0.1mM palmitate or 10mM 
glutamine + 10mM leucine and incubated for two hours (37˚C, 5% CO2).  After incubation, 
media containing treatments was removed and 200µL of cell extraction buffer (supplemented 




added.  Wells were scraped and wells containing the same treatment were combined and 
transferred to a 1.5mL tube and stored at -20˚C. 
 Protein samples were thawed and centrifuged at 12,500 rpm for 20 minutes at 4˚C.  The 
supernatant was transferred to a 1.5mL tube.  Protein concentration was measured using a BCA 
assay.  Protein samples were stored at -20˚C until co-immunoprecipitation was performed. 
 
3.4.2 Co-immunoprecipitation 
 Co-immunoprecipitation was performed using Dynabeads
®
 Protein G co-
immunoprecipitation kit (Novex by Life Technologies, Mississauga, ON).  Dynabeads
®
 were re-
suspended by vortexing for 30 seconds and 50µL was transferred to a 1.5mL tube for each 
treatment.  The tubes were placed on a DynaMag
™ 
magnet (Life Technologies, Mississauga, 
ON) and the supernatant was removed.  Anti-hydroxyproline antibody (Abcam, Toronto, ON) 
was diluted in antibody binding and washing solution (Novex by Life Technologies, 





complex was incubated for 10 minutes using the HulaMixer
®
 Sample Mixer (Life Technologies, 
Mississauga, ON).  The supernatant was removed and the Dynabeads
®
-Ab complex was washed 
with antibody binding and washing solution.  
 Dynabeads
®
-Ab complex was crosslinked using 5mM crosslinking reagent 
bis(sulfosuccinimidyl)suberate (BS3) (100mM BS3 stock diluted in PBS) (Thermo Scientific, 
Mississauga, ON) to prevent co-elution of the anti-hydroxyproline antibody.  200µL of 5mM 
BS3 solution was added to each tube and incubated at room temperature for 30 minutes using the 
sample mixer.  12.5µL of Quenching Buffer (Thermo Scientific, Mississauga, ON) was added to 




200µL of antibody binding and washing solution and the supernatant was removed using the 
magnet.  175µL of protein sample containing approximately 1mg of protein was added to each 
tube and incubated for 10 minutes using the sample mixer.  After incubation, the tubes were 
placed on the magnet and the supernatant was removed and transferred to a new 1.5mL and 
stored at -20˚C.  
 The Dynabeads
®
-Ab-antigen complex was washed three times with 200µL of washing 
buffer (Novex by Life Technologies, Mississauga, ON).  The tubes were placed on the magnet 
and the supernatant was re-suspended with 100µL of washing buffer.  The bead suspension was 
transferred to a new 1.5mL tube.  The tubes were placed on the magnet and the supernatant was 
removed.  20µL of Elution Buffer and 10µL of premixed NuPAGE
®
 LDS Sample Buffer and 
NuPAGE Sample Reducing Agent (Life Technologies, Mississauga, ON) were added to each 
tube containing the Dynabeads
®
-Ab-antigen complex.  The tubes were re-suspended by inverting 
and samples were heated for 10 minutes at 70˚C.  The tubes were placed on the magnet and the 
supernatant containing 1mg of antigen was loaded onto a NuPage
®
 10% Bis-Tris SDS 
Polyacrylamide Mini Gel (Thermo Scientific, CA, USA) for 50 minutes.  The gel was placed in 
10% methanol, 10% glacial acetic acid overnight at 4˚C.  
 
3.4.3 Silver staining 
The gel containing prolyl hydroxylated protein was removed from 10% methanol, 10% 
glacial acetic acid solution and washed twice with deionized water and then washed three times 
for 10 minutes in deionized water on a shaker.  The gel was incubated in sodium thiosulfate 
(0.04g in 5 mL milliQ water) for 90 seconds.  The gel was washed three times with deionized 




a shaker, staining the gel.  The gel was washed three times with deionized water.  Developer 
solution (1g potassium carbonate, 2mL diluted sodium sulfate, 23.1µL of 37% formaldehyde) 
was added and incubated until protein bands appeared.  Developer solution was removed and the 
reaction was stopped with destain solution (10% methanol, 10% glacial acetic acid) for less than 
five minutes.  Destain solution was removed and the gel was placed in milliQ water and stored at 
4˚C until protein bands were excised.  
Protein bands were excised using a blade washed with 70% ethanol between each cut to 
avoid contamination.  Bands were cut 1-1.5mm wide and placed in 250µL of 5% acetic acid. 
Samples were stored at 4˚C until delivered to the MALDI-MS facility in the department of 
biochemistry at Western University for protein identification by MALDI-MS. 
 
3.4.4 Matrix assisted laser desorption/ionization mass spectrometry (MALDI-MS) 
 Excised protein bands were delivered to the MALDI MS facility at Western University 
where an in-gel digestion was performed using a MassPREP automated digester station 
(PerkinElmer, Waltham, MA, USA).  Protein bands were reduced using 10mM dithiotreitol 
(DTT) followed by alkylation using 55mM iodoacetamide (IAA) and digested using trypsin 
(prepared in 50mM ammonium bicarbonate, pH 8).  Samples containing trypsin were incubated 
overnight at 20˚C to allow for trypsin absorption.  The samples were incubated at 40˚C for seven 
hours.  Peptides were extracted from the gel using 1% formic acid, 2% acetonitrile.  Peptides 
were lyophilized and stored at -20˚C.  Prior to MALDI TOF/TOF, peptides were reconstituted in 
10% acetonitrile, 0.1% trifluoroacetic acid (TFA).  
 MALDI TOF/TOF MS was performed using AB Sciex 5800 TOF/TOF System 




MALDI matrix α-cyano-4-hydroxycinnamic acid (CHCA) (prepared as 5mg/mL in 6mM 
ammonium phosphate monobasic, 50% acetonitrile, 0.1% trifluoracetic acid) at a 1:1 ratio.  The 
matrix-peptide solution was spotted on a MALDI plate and vaporized, which allowed the matrix 
and unknown peptides to co-crystallize.  A 349 nm Nd:YLF OptiBeam On-Axis laser was aimed 
at the crystals to desorb and ionize the matrix crystals.  The laser pulse rate was 400 Hz.  The     
unknown peptide crystals were protonated via the ionized matrix.  The same amount of kinetic 
energy was applied to all ions produced, allowing the ions to accelerate towards the reflectron 
detector.  The reflectron mode was externally calibrated at 50 ppm mass tolerance and internally 
at 10 ppm.  Each mass spectrum was collected as a sum of 500 shots.  Using KE=1/2mv
2
, the 
mass of each ion was determined, as the ions reached the detector at different times.  
The instrument performed partial peptide sequencing and identification of post-
translational modifications of selected ions.  Sequence databases were searched using MASCOT. 
SwissProt, NCBIprot and EMBLE EST division databases were used for peptide mass 
fingerprinting and protein identification.  Contaminants and CRAP databases were used to search 
for common contaminants present in the unknown peptide samples.  
3.5 Statistical analysis 
 All results are expressed as mean ± SEM.  Statistical significance was measured using 









Chapter 4: Results 
4.1 Confirmation of PHD expression in 832/13 cells by western blot analysis 
 PHD1, PHD2, and PHD3 expression was confirmed in 832/13 cells by western blot 
analysis.  Approximately 20µg of isolated protein sample from 832/13 cells were incubated with 
LG (2mM) KRB for one hour (37˚C, 5% CO2) to stimulate basal insulin secretion.  Primary 
antibodies for PHD1, PHD2, PHD3, and tubulin were used to determine protein expression semi-
quantitatively using Imagej (fig.4.1).  Background noise was subtracted and relative density was 











Figure 4.1: Western blot analysis using Imagej. 
 PHD1 peaks in 832/13 cells stimulated with LG (2mM) KRB are shown in the profile plot 
above.  Relative density for each protein band was measured and background noise was 
subtracted.  The percentage of the total size of the peak was measured using Imagej and 
corrected using tubulin.  The average corrected value was calculated using two protein samples 
treated with LG (2mM) KRB and the relative density was calculated by dividing the corrected 
values by the average.  Relative density calculations for PHD1, PHD2, and PHD3 are 
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PHD1 44 LG1 13975.05 56.832 1.142214 1.000691 1.141426 
  LG2 10615.15 43.168 0.859167  0.858574 
PHD2 50 LG1 1200.59 24.138 0.485127 0.499928 0.970395 
  LG2 12857.54 25.862 0.514728  1.029605 
PHD3 47 LG1 7283.426 49.787 1.000623 1.000003 1.00062 
  LG2 7345.841 50.213 0.999383  0.99938 
Tubulin 50 LG1 10616.45 49.756    
  LG2 10720.45 50.244    
 
Area under the peak and percentage of the total size of the peak were calculated using imageJ.  
The percentage of the size of the peak was corrected using tubulin and the corrected values were 
averaged for each isoenzyme.  Two samples for each isoenzyme were used to calculate protein 
expression (LG1 and LG2).  The relative density of the protein bands were calculated by 








Figure 4.2: PHD expression in 832/13 cells by western blot analysis.  
Approximately 20µg of total protein was isolated from 832/13 cells and protein concentration 
was determined by a BCA protein assay.  Protein samples were analyzed by western blot for 
expression of all three PHD isoenzymes.  Tubulin was used as a control.  Results shown are from 
two samples treated with LG (2mM) KRB and protein intensity was measured by Imagej.  PHD1 












4.2 Confirmation of PHD expression in mouse pancreases by immunofluorescence 
 Expression and subcellular localization of PHD1, PHD2, and PHD3 was confirmed by 
immunofluorescence in mouse pancreases.  Primary antibodies for PHD1, PHD2, PHD3, and 
insulin; and Alex Fluor® 488 and Alexa Fluor® 647 secondary antibodies were used.  It was 
determined that all three isoenzymes are expressed in the mouse pancreas with distinct 
subcellular localizations.  Insulin is exclusively expressed in the cytosol within β-cells of islets 
(fig.4.3 A).  PHD1 was found to be expressed in the cytosol of both islets and acinar tissue 
(fig.4.3 B).  PHD2 was found to be expressed mainly in the cytosol of both islets and acinar 
tissue with a weak nuclear stain (fig.4.3 C), whereas PHD3 was found to be expressed mainly in 
the nucleus of both islets and acinar tissue with a weak cytosolic stain (fig.4.3 D).  All PHD 
isoenzymes were expressed in islets and overlapped with insulin, suggesting that all three 












Figure 4.3: PHD expression in mouse pancreases. 
Immunofluorescence staining of mouse pancreases aged 10-14 weeks.  Formalin-fixed paraffin-
embedded tissue slides were stained using primary antibodies for PHD1, PHD2, PHD3, and 
insulin.  Alexa Fluor® 488 and Alexa Fluor® 647 secondary antibodies were used for insulin 
and PHD primary antibodies, respectively.  Insulin alone was used as a control. (a) Staining with 
insulin antibody alone showed a strong stain for insulin exclusively in the cytosol of β-cells. (b) 
Staining with insulin and PHD1 antibodies showed a strong cytosolic stain for PHD1 in acinar 
tissue and islets. (c) Staining with insulin and PHD2 antibodies showed a strong cytosolic stain 
for PHD2 in both acinar tissue and islets and a weak nuclear stain. (d) Staining with insulin and 
PHD3 antibodies showed a strong nuclear stain for PHD3 in acinar tissue and islets with a weak 





4.3 OCR is decreased in 832/13 cells and primary mouse islets treated with DMOG using 
Seahorse Bioscience XF24 Respiration Assay 
 OCR was measured in 832/13 cells and primary mouse islets to determine if oxygen 
consumption, and therefore, mitochondrial respiration was affected in cells and islets treated with 
the pharmacological inhibitor, DMOG.  Oxygen consumption was measured in 832/13 cells 
treated with 200µM, 500µM, and 1000µM DMOG compared to NT containing HG (16.7mM) 
KRB (fig.4.4 A) and mouse islets treated with 1mM, 5mM, and 10mM DMOG compared to NT 
containing HG (16.7mM) KRB (fig.4.5 A).  OCR was significantly reduced in 832/13 cells at 
200µM, 500µM and 1000µM DMOG compared to NT when stimulated with HG and pyruvate + 
DNP.  Area under the curve (AUC) was calculated from (fig.4.5 A).  Islets treated with 5mM 
DMOG displayed significantly reduced OCR values compared to NT when islets were 
stimulated with HG (p<0.05) and DNP + DMM + DMαKG (p<0.05) (fig.4.5 B) 
Oligomycin treatment resulted in decreased oxygen consumption in both 832/13 cells 
(fig.4.4 A) and primary islets (fig.4.5 A), representing the ATP that would be produced via 
mitochondrial respiration.  Oligomycin OCR values were used to calculate ATP turnover and 
proton leak.  Proton leak was not statistically different in DMOG treated cells compared to NT 
(fig. 4.4 B).  However, there was a reduced trend in proton leak in 832/13 cells treated with 
DMOG at all concentrations, suggesting more H
+ 
are contributing to ATP production via ATP 
synthase.  There was a statistically significant reduction in ATP turnover in 832/13 cells at 
200µM (p<0.01), 500µM (p<0.001) and 1000µM (p<0.001) DMOG (fig.4.4 C) and at 1mM 
(p<0.05) and 5mM (p<0.05) DMOG in primary islets (fig. 4.5 D).  ATP turnover represents ATP 
produced from mitochondrial respiration.   Inhibition of PHD via DMOG results in reduced 




results suggest that PHD plays a role in oxidative metabolism, decreasing the ATP/ADP ratio 
required for the KATP channel-dependent pathway.  
Pyruvate, DMM, and DMαKG are TCA cycle intermediates that stimulate oxidative 
metabolism.  DNP, a proton ionophore, dissipates the H
+
 gradient and collapses the proton 
motive force allowing electron flow through the ETC to be uninhibited.  These drugs were used 
to stimulate maximal respiration and to measure spare respiratory capacity.  Spare respiratory 
capacity measures the ability of the cell to respond to an increase in energy demand, an indicator 
of cell fitness.  Spare respiratory capacity was significantly reduced at 1000µM DMOG (p<0.05) 
in 832/13 cells (fig. 4.4 D). 
Rotenone and myxothiazol, inhibitors of complex I and complex III in the ETC, 
respectively, were used to measure non mitochondrial oxygen consumption.  Rotenone and 
myxothiazol treatment measures oxygen consumption that continues when oxidative metabolism 
is inhibited due to enzymes that consume oxygen, such as PHD.  Non mitochondrial oxygen 
consumption was significantly reduced at 1000µM DMOG (p<0.001) in 832/13 cells (fig. 4.4 E).  
There was a reduced trend in non-mitochondrial oxygen in primary islets treated with 5mM and 
10mM DMOG (fig. 4.5 C).  
Respiration assays in 832/13 cells and primary mouse islets show that inhibition of PHD 
via DMOG results in decreased oxygen consumption and alters parameters of mitochondrial 
function.  Decreased OCR when PHD is inhibited may indicate improved mitochondrial 









Figure 4.4: OCR in 832/13 cells. 
Mitochondrial respiration summary in 832/13 cells is shown above.  OCR was measured over 
150 minutes using Seahorse XF24 Respiration Assay. (n=5). Assay was repeated 4 times.  Data 
are mean ± SEM. (a) OCR was measured in the presence of HG (16.7mM) KRB for 40 minutes, 
oligomycin (10µM) for 25 minutes, DNP (50µM) + pyruvate (20mM) for 30 minutes, and 
rotenone (5µM) + myxothiazol (5µM) for 30 minutes.  832/13 cells were treated with 200µM, 
500µM, and 1000µM DMOG compared to NT. ***p<0.001 at 200µM, 500µM, and 1000µM 
DMOG, **p<0.01 at 200µM and 500µM DMOG, ***p<0.001 at 1000µM DMOG by a paired t-
test. (b) Proton leak was calculated by subtracting rotenone + myxothiazol OCR values from 
oligomycin OCR values. (c) ATP turnover was calculated by subtracting oligomycin OCR 
values from HG (16.7mM) OCR values.  **p<0.01, ***p<0.001, ***p<0.001 by a paired t-test.  
(d)  Spare respiratory capacity was calculated by subtracting basal OCR values from DNP + 
pyruvate OCR values. *<0.05 by a paired t-test.  (e) Non mitochondrial oxygen consumption was 










Figure 4.5: OCR in primary mouse islets. 
Mitochondrial respiration summary in primary mouse islets from male C57BL/6J mice aged 10 
weeks.  OCR was measured over 220 minutes using Seahorse XF24 Respiration Assay. (n=5).  
Assay was repeated twice.  Data are mean ± SEM.  (a)  OCR for primary mouse islets treated 
with 1mM, 5mM, and 10mM DMOG injected with HG (16.7mM) KRB for 60 minutes, 20µM 
oligomycin for 50 minutes, 100µM DNP + 10mM DMM + 10mM DMαKG for 45 minutes, and 
10µM rotenone + 10µM myxothiazol for 40 minutes.  (b)  AUC of A. *p<0.05, *p<0.05 by a 
paired t-test.  (c)  Non mitochondrial oxygen consumption was determined by rotenone + 
myxothiazol OCR values.  (d)  ATP turnover was calculated by subtracting oligomycin OCR 
values from basal OCR values. *p<0.05, *p<0.05 by a paired t-test.   
4.4 PHD inhibition using DMOG may enhance pancreatic β-cell insulin secretion 
 A GSIS was performed to assess whether PHD plays a role in pancreatic β-cell insulin 
secretion.  Islets were isolated from male C57BL/6J mice and incubated overnight (37˚C, 5% 
CO2).  The following day, islets were dispersed and a GSIS was performed on day 3.  Dispersed 
islets were treated with LG (2mM) KRB, HG (16.7mM) KRB,  LG (2mM) KRB + 5mM 




unaltered in dispersed islets treated with 5mM DMOG compared to NT when stimulated with 
LG (2mM) KRB.  There was an increased trend in insulin secretion in dispersed islets treated 
with 5mM DMOG compared to NT when stimulated with HG (16.7mM) KRB.  Acute inhibition 
of PHD via DMOG may play a role in GSIS.   
 
Figure 4.6: GSIS in primary mouse islets treated with 5mM DMOG. 
Insulin secretion from C57BL/6J male mice aged 10-14 weeks.  Dispersed islets were treated 
with 5mM DMOG compared to NT.  Insulin secretion was measured in response to either LG 
(2mM) or HG (16.7mM) KRB.  Insulin secretion was determined by RIA. Assay repeated three 
times in triplets.  Data are mean ± SEM.  
4.5 Inhibition of PHD using DMOG increases second phase insulin secretion 
 The role of PHD in second-phase insulin secretion was investigated by performing a 
perifusion assay.  Dynamic insulin secretion was measured to determine whether there is a 




DMOG.  Islets were stimulated with LG (2mM) KRB for the first 10 minutes to measure basal 
insulin secretion, HG (16.7mM) KRB or HG (16.7mM) KRB + 5mM DMOG for 40 minutes, 
and HG (16.7mM) KRB + KCl (30mM) for 15 minutes.  Insulin secretion was significantly 
increased at 45 minutes (p<0.05) and 48 minutes (p<0.05) when treated with HG (16.7mM) KRB 
+ 5mM DMOG compared to HG (16.7mM) KRB (fig.4.7 A).  AUC revealed a statistically 
significant increase in GSIS in islets treated with HG (16.7mM) KRB + 5mM DMOG in the 
latter 30 minutes compared to NT (p<0.01) (fig.4.7 B).  These results demonstrate that inhibition 
of PHD via DMOG enhances second-phase GSIS when stimulated with HG.   
 Total insulin content was measured in each chamber containing islets with the addition of 
extraction buffer.  Total insulin content remained unchanged in DMOG treated islets compared 







Figure 4.7: Perifusion in primary mouse islets treated with 5mM DMOG. 
Islet perifusion measuring dynamic insulin secretion from C57BL/6J male mice aged 10-14 
weeks over 65 minutes.  Insulin secretion was determined by RIA. Assay repeated three times in 
triplets.  Data are mean ± SEM.  (a)  Islets were stimulated with LG (2mM) KRB for 10 minutes, 
HG (16.7mM) KRB or HG (16.7mM) KRB + 5mM DMOG for 40 minutes and HG (16.7mM) 
KRB + KCl (30mM) for 15 minutes. *p<0.05, *p<0.05 by a one-way ANOVA.  (b)  AUC of A. 





4.6 Inhibition of PHD using DMOG improves glucose tolerance in C57BL/6J male mice 
 Inhibition of PHD via 5mM DMOG resulted in enhanced second-phase insulin secretion 
in vitro.  The role of PHD in glucose homeostasis was next assessed in vivo using C57BL/6J 
male mice aged 10-14 weeks was assessed.  Mice were injected intraperitoneally with 200µg/g 
body weight DMOG or PBS 30 minutes prior to an exogenous glucose load.  All mice were 
injected intraperitoneally with 1.5g/kg body weight glucose and blood glucose levels were 
measured over a two hour period.  Blood glucose levels remained unchanged during the first 30 
minutes after a glucose challenge.  Mice injected with 200µg/g body weight DMOG 
demonstrated improved glucose tolerance compared to PBS control mice at 90 minutes (p<0.05) 
and 120 minutes, although not statistically significant, after a glucose challenge (fig.4.8 A).  
These results further support the role of PHD in second-phase insulin secretion.  Blood samples 
from the tail vein were collected at baseline, 10 and 30 minutes after a glucose injection and 
plasma insulin was measured by ELISA.  Despite unchanged blood glucose levels during the 
first 30 minutes, mice injected with 200µg/g body weight DMOG demonstrated significantly 
reduced plasma insulin levels at 10 minutes (p<0.01) after glucose injection (fig.4.8 B).  These 
findings suggest inhibition of PHD via 200µg/g body weight DMOG results in improved insulin 
sensitivity compared to PBS control mice.  Inhibition of PHD via DMOG results in improved 
glucose tolerance during second-phase insulin secretion but may also play a role in first-phase 










Figure 4.8: In vivo glucose homeostasis in C57BL/6J mice treated with DMOG. 
Effects of DMOG (200µg/g body weight) on in vivo glucose homeostasis in C57BL/6J male 
mice aged 10-14 weeks. (n=12). Data are mean ± SEM.  (a)  Blood glucose levels during an 
ipGTT over a two hour period. *p < 0.05 at 90 minutes by a one-way ANOVA.  (b)  Plasma 
insulin levels measured by an ELISA at baseline, 10 minutes and 30 minutes. **p<0.01 at 10 




4.7 Development of a β-cell specific KO model 
 Two transgenic mouse lines with floxed exons (exon 3 for PHD1 and exon 2 for PHD2 
and PHD3), PHD123fl/fl and PHD2fl/fl, were bred with C57BL/6J mice for three backcrosses 
and genotyped monthly (fig.4.9).  The PHD123fl/fl line was isolated, generating PHD1+/fl 
(fig.4.10 A) and PHD3+/fl (fig.4.10 C) and these mice were bred with Ins-1
Cre
 mice (fig.4.10 D).  
Heterozygous mice for PHD1 and PHD3 with Cre recombinase inserted into the β-cell specific 
Ins-1 gene to target loxP sites on either side of exon 3 or exon 2 for PHD1 and PHD3, 
respectively were generated (PHD1+/fl/Cre, PHD3+/fl/Cre).  After back crossing with 
C57BL/6J mice for three generations PHD2+/fl (fig.4.10 B) mice were isolated from the 
PHD2fl/fl mouse line.  PHD2+/fl mice were bred with Ins-1
Cre
 and heterozygous mice for PHD2 
with β-cell specific Cre recombinase were generated (PHD2+/fl/Cre).   
 PHD1+/fl/Cre, PHD2+/fl/Cre and PHD3+/fl/Cre mice were bred together (not from the 
same litter) to generate WT (PHD+/+/Cre), heterozygous (PHD+/fl/Cre) and KO (PHDfl/fl/Cre) 
mice for each PHD isoenzyme.  The objective of developing three independent transgenic mouse 
lines is to conduct in vitro and in vivo experiments, assessing the long term effects of PHD in 
regulating pancreatic β-cell insulin secretion in a KO animal model.  These results suggest 
pharmacological inhibition of PHD via DMOG augments second-phase insulin secretion in vitro 
and improves glucose tolerance in vivo, demonstrating the role of PHDs in short term regulation 
of insulin secretion.  Future work involving β-cell specific PHD KO mice from the time of birth 
will investigate the long term effects of PHD in regulating insulin secretion and will explore 





Figure 4.9: Genotyping of PHD123fl/fl and PHD123+/fl F1 generation mice by PCR 
analysis. 
The PHD123fl/fl mouse line was purchased from Dr. Guo-Hua Fong from the University of 
Connecticut (Farmington, CT, USA).  C57BL/6J mice were used for back crossing and were 
purchased from Jackson Laboratories (Bar Harbor, ME, USA).  Primers were obtained from 
Integrated DNA Technologies (Coralville, IA, USA).  (a)  Genotyping for PHD1fl/fl and 
PHD1+/fl mice.  WT protein band was 500 bp and floxed protein band was 600 bp.  (b)  
Genotyping for PHD2fl/fl and PHD2+/fl mice.  WT protein band was 1400 bp and floxed protein 
band was 1900 bp.  (c)  Genotyping for PHD3fl/fl and PHD3+/fl mice.  WT protein band was 





Figure 4.10: Genotyping of PHD+/fl/Cre, PHD+/+/Cre, and Ins-1
Cre
 mice by PCR analysis. 
PHDfl/fl mice were back crossed three generations with C57BL/6J mice.  PHD+/fl were crossed 
with Ins-1
Cre
 to generate PHD+/fl/Cre and PHD+/+/Cre F1 mice.  Ins-1
Cre
 mice were obtained 
from Jackson Laboratories (Bar Harbor, ME, USA).  Primers were obtained from Jackson 
Laboratories (Bar Harbor, ME, USA) or Integrated DNA Technologies (Coralville, IA, USA).  
(a)  Genotyping for PHD1+/fl X Ins-1
Cre
 mice.  WT protein band was 500 bp and floxed protein 
band was 600 bp.  (b) Genotyping for PHD2+/fl X Ins-1
Cre
 mice.  WT protein band was 1400 bp 
and floxed protein band was 1900 bp.  (c)  Genotyping for PHD3+/fl X Ins-1
Cre
 mice.  WT 
protein band was 1070 bp and floxed protein band was 1550 bp.  (d)  Genotyping of Ins-1
Cre 
mice.  Common (WT) protein band was 488 bp and mutant (Cre expressing) protein band was 




4.8 Identifying prolyl hydroxylated proteins by PHD 
 Short term inhibition of PHD via DMOG plays a role in GSIS in vitro and improves 
glucose tolerance in vivo.  Since PHDs regulate proteins via prolyl hydroxylation, the next 
objective was to identify proteins with proline hydroxylation to explore whether PHD prolyl 
hydroxylated proteins have short term effects on insulin secretion.  Co-immunoprecipitation 
using whole cell lysates from 832/13 cells was performed.  An anti-hydroxyproline antibody was 
used to bind proteins with hydroxylated proline residues from protein samples treated with NT 
(cell growth media), LG (2mM) KRB, HG (16.7mM) KRB, glutamine (Glu) (10mM) + leucine 
(Leu) (10mM) and palmitate (Pal) (0.1mM) to investigate whether nutrient stimuli alters protein.  
Protein samples containing 1mg of protein were also treated with DMαKG (10mM) and DMOG 
(500µM) as positive and negative controls for PHD, respectively.  After co-immunoprecipitation, 
gel electrophoresis was performed followed by silver staining of the polyacrylamide gel (fig. 
4.11).    
 Protein bands from LG (2mM) KRB (38 kDa and 41 kDa), NT (20 kDa, 30 kDa, 38 kDa, 
40 kDa, 60 kDa and 140 kDa), palmitate (0.1mM) (20 kDa, 38 kDa and 140 kDa) and DMαKG 
(10mM) (40kDa) were excised using a razor blade and delivered to Western University for 





Figure 4.11: Silver stained gel containing prolyl hydroxylated protein from 832/13 cells. 
Protein bands were excised from a silver stained polyacrylamide gel containing prolyl 
hydroxylated protein from 832/13 cells.  38 kDa and 41 kDa protein bands were excised from 
LG (2mM) KRB; 20 kDa, 30 kDa, 38 kDa, 40 kDa, 60 kDa and 140 kDa protein bands were 
excised from NT (cell media); 20 kDa, 38 kDa and 140 kDa protein bands were excised from 
palmitate (0.1mM) treatment; and a 40 kDa protein band was excised from DMαKG (10mM) 
treatment.  Protein band lengths are approximate.  
 
 Glucose (LG, HG), amino acids (glutamine + leucine) and saturated fatty acids 
(palmitate) were used to investigate whether prolyl hydroxylated protein expression was affected 
by nutrient stimuli.  20 kDa and 38 kDa protein bands were observed to be downregulated when 
treated with LG (2mM) KRB, palmitate (0.1mM), and glutamine (10mM) + leucine (10mM) 




with palmitate and glutamine + leucine and unobserved in the LG treatment compared to NT; 
however, we were unable to excise protein bands from glutamine + leucine treatment.  These 
observations suggest that nutrient stimuli regulate prolyl hydroxylated proteins.  It is 
hypothesized that the unidentified proteins are proline hydroxylated via PHD and are regulated 
by nutrient stimuli.  Previous experiments suggest that short term inhibition of PHD results in 
enhanced second-phase insulin secretion.  It can be suggested that inhibition of PHD results in 
upregulation of unidentified proteins to enhance insulin secretion.  
 Protein bands were excised using a razor blade.  Excised protein bands were stored in 5% 
acetic acid and delivered to the MALDI-MS Facility at Western University (London, ON, CA) 
for protein identification by MALDI-MS.  Peaks Software using the hydroxyl modification of 
proline was used; however, prolyl hydroxylated proteins in the samples were unable to be 















Table 4.2: Protein identification by MALDI-MS data 
Sample Size (kDa) 
LG (2mM) 41 







Palmitate (0.1mM) 140 
Palmitate (0.1mM) 38 
Palmitate (0.1mM) 20 
DMαKG (10mM) 40 
 
12 Protein bands were excised from a silver stained polyacrylamide gel treated with LG (2mM), 
NT, Palmitate and DMαKG.  Protein bands of approximate size were excised across treatments 
for comparison.   
    
 








Chapter 5: Discussion 
5.1 Summary 
 The data presented in chapter four reveal the acute effects of PHD in oxidative 
mitochondrial metabolism and GSIS using the pharmacological inhibitor DMOG.  PHD 
inhibition via DMOG resulted in a significant reduction in ATP turnover, spare respiratory 
capacity and non-mitochondrial oxygen consumption in 832/13 cells.  Similarly, inhibition of 
PHD via DMOG resulted in decreased ATP turnover in primary mouse islets.  The role of PHD 
in GSIS and glucose homeostasis was also assessed.  Inhibition of PHD via 5mM DMOG 
resulted in enhanced second-phase insulin secretion in vitro, suggesting PHD plays a role in 
KATP channel-independent pathways.  PHD inhibition in C57BL/6J male mice led to improved 
glucose tolerance at 90 and 120 minutes after an exogenous glucose load in vivo, further 
supporting PHD’s involvement in second-phase insulin secretion.  ELISA revealed inhibition of 
PHD results in decreased plasma insulin levels 10 minutes after a glucose challenge despite 
unchanged blood glucose levels.  Improved insulin sensitivity at 10 minutes in vivo and 
decreased ATP turnover in vitro suggests that PHD may also play a role in the KATP channel-
dependent pathway. 
5.2 Expression of PHD isoenzymes in 832/13 cells and primary mouse islets 
 Western blot analysis using specific PHD primary antibodies, determined that PHD1, 
PHD2, and PHD3 are expressed in 832/13 cells.  As well, all PHD isoenzymes are expressed 
with unique subcellular localizations in mouse pancreases, which was determined by 
immunofluorescence.  PHD1 is expressed exclusively in the cytosol within acinar tissue and 




nuclear stain, and PHD3 is expressed mainly in the nucleus within the acinar tissue and islets 
with a weak cytosolic stain.  
 However, PHD expression differs between the mouse and human pancreas.  In the human 
pancreas, PHD1 and PHD2 are expressed in the cytosol within islets, acinar tissue and pancreatic 
ducts, whereas PHD3 is expressed in the cytosol and nucleus within islets, acinar tissue and 
pancreatic ducts.
57
 Differences in PHD expression between mice and human pancreases may be 
associated with differences in islet composition and organization.   
 Several rodent models have been developed to study pancreas physiology in T2D.
113
 It is 
important to consider the differences between human and mice pancreases since findings from 
rodent models are generalized to humans.
113
 Anatomically, the human pancreas is definite, with a 
distinct head, body, and tail, whereas the mouse pancreas is divided into 3 less-defined lobes.
113
 
The endocrine portion of the pancreas consists of 50-70% and 60-80% β-cells within the islet for 
humans and mice, respectively.
113,114
 In rodents, β-cells comprise the core of the islet surrounded 
α-cells.
114
 In humans, islets form a trilaminar plate consisting of a layer of β-cells surrounded by 
two layers of α-cells, which forms a U or O-shaped islet.
113
 Human β-cells  respond to lower 
blood glucose concentrations compared to mice.
113,115
 Despite differences in endocrine cell 
distribution between mice and humans, islet size remains relatively the same in both species.
115
   
 Rodents and humans also display differences in oxidative metabolism and β-cell insulin 
secretion.  PC is involved in pyruvate cycling, producing NADPH and αKG via the 
pyruvate/isocitrate pathway.  It is hypothesized that cytosolic αKG acts as a co-substrate for 
PHD to regulate insulin secretion.  However, PC was found to be reduced by 80-90% in human 
islets compared to mouse islets and 832/13 cells.
43




human islets through PC was 20 to 30%, whereas pyruvate entering the TCA cycle through PC is 
approximately 50% in rodent models.
43,44 
5.3 OCR in 832/13 cells and primary mouse islets 
5.3.1 In vitro findings of OCR in 832/13 cells  
 Oxidative metabolism was significantly decreased in 832/13 cells treated with DMOG.  
Proton leak, H
+
 that is not coupled to ATP production, can be an indication of mitochondrial 
damage or a means of regulating ATP production.  Proton leak was not significantly altered in 
DMOG treated cells but a reduced trend was observed.  ATP turnover was decreased at all 
concentrations of DMOG, and spare respiratory capacity and non-mitochondrial oxygen 
consumption was significantly decreased at 1000µM DMOG. 
 
5.3.2 In vitro findings of OCR in primary mouse islets 
     Oxidative metabolism was reduced in primary mouse islets treated with DMOG.  OCR 
was decreased in islets treated with 5mM DMOG compared to NT when stimulated with  HG 
(16.7mM) KRB and HG (16.7mM) KRB + DMM (10mM) + DMαKG (10mM) .  There was a 
decreased trend for non-mitochondrial oxygen consumption, which is due to pathways other than 
oxidative respiration, with the greatest decrease at 5mM DMOG.  ATP turnover was 
significantly reduced at 1mM and 5mM DMOG.  Respiration assays demonstrate the role of 
PHD in mitochondrial metabolism.  Inhibition of PHD via DMOG decreased OCR and 







5.3.3 OCR levels are decreased with PHD inhibition in 832/13 cells and primary mouse islets 
  OCR experiments reveal insights into metabolic activity by measuring parameters of 
mitochondrial metabolism in real time.  These results show a significant decrease in oxygen 
consumption when 832/13 cells and primary mouse islets were treated with DMOG at HG 
(16.7mM) KRB.  β-cells demonstrate increased rates of oxidative metabolism, requiring large 
quantities of oxygen for survival.
116
 Islets are exposed to a higher partial pressure of oxygen 
compared to acinar tissue and are highly vascularized, demonstrating the metabolic demand of β-
cells.
116
 OCR is a parameter of β-cell function and represents the amount of energy released 
during oxidative metabolism.
116
 Komatsu and colleagues  (2016) incubated human islets in either 
a hypoxic, normoxic or hyperoxic environment and measured OCR.  OCR levels were increased 
in islets incubated in a hyperoxic environment.  DMOG is an effective hypoxia mimetic and 
inhibition of PHD via DMOG resulted in reduced OCR levels in 832/13 cells and islets.  Leung 
and colleagues (2017) investigated the role of HIF1α in oxidative metabolism and HIF1α 
knockdown in ME180 and FaDu cells resulted in decreased lactate production and significantly 
increased OCR levels when exposed to a hypoxic environment, possibly resulting in increased 
hypoxia.
117
 Inhibition of PHD via DMOG may lead to HIF1α stabilization at higher 
concentrations, and the findings presented in chapter four indicate that inhibition of PHD in both 
832/13 cells and primary mouse islets results in decreased OCR compared to NT.  The potential 
role of HIFα in decreasing OCR levels cannot be eliminated however; these results demonstrate 
the acute effects of PHD, which may be involved in non-HIFα-dependent pathways.  
 Glucose metabolism via mitochondrial respiration is linked to insulin secretion.
118
 First-
phase insulin secretion relies on increased ATP production from mitochondrial metabolism and 




specifically, impairments with mitochondrial membrane potential.
118
 A decreased response of 
membrane potential to a glucose stimulus decreases OCR levels and negatively affects 
mitochondrial bioenergetics.
118
       
 Inhibition of PHD via DMOG was shown to alter parameters that represent mitochondrial 
function in both cells and islets.  There was a reduced trend in proton leak in 832/13 cells treated 
with DMOG at all concentrations.  Proton leak is the amount of H
+
 that does not contribute to 
ATP production and is dissipated as heat.  Increased proton leak could be a sign of mitochondrial 
damage or a means to regulate ATP production.  Decreased proton leak suggests more H
+
 ions 
are contributing to ATP production by ATP synthase.  Uncoupling protein-2 (UCP-2) is an inner 
mitochondrial membrane protein that dissipates the proton motive force when glucose and fatty 
acids are abundant.
8,119
 UCP-2 is induced in chronic glucose and fatty acid overload to aid in 
ROS reduction.
8
  However, UCP-2 results in reduced ATP production and is associated with β-
cell dysfunction and the development of T2D.
8,119
 Hu and colleagues (2017) showed that 
palmitate treatment in 832/13 cells triggers UCP-2 activity resulting in impaired GSIS.  ATP 
turnover was significantly reduced in both 832/13 cells and primary mouse islets.  Reduced ATP 
synthesis via mitochondrial metabolism eventually leads to impaired GSIS and the onset of 
T2D.
119
 Despite observing reduced ATP turnover in 832/13 cells and primary mouse islets, 
insulin secretion was increased in GSIS assays in primary mouse islets treated with DMOG in 
vitro.  Gerenscer (2017) and colleagues determined that proton leak and ATP turnover regulate 
steady state membrane potential at LG (2mM) but not at HG (10mM) via determination of 
membrane potential values by fluorescence microscopy.  
Spare respiratory capacity was decreased at 1000µM DMOG in 832/13 cells and is the 




findings suggest that perhaps at high concentrations of DMOG in 832/13 cells, the β-cell is 
unable to effectively respond to an increase in energy demand but may also be due to off target 
effects.  Decreased ATP production and spare respiratory capacity are correlated to T2D and 
indicate mitochondrial dysfunction.
120
 Inhibition of PHD via DMOG reduces ATP production 
and spare respiratory capacity and in part, may regulate the KATP channel-dependent pathway by 
decreasing the ATP/ADP ratio at high concentrations of DMOG.   
Non mitochondrial oxygen consumption is the amount of oxygen consumption that 
continues due to other metabolic pathways or enzymes.  Non mitochondrial oxygen consumption 
was significantly reduced at 1000µM DMOG in 832/13 cells and reduced at 5mM and 10mM 
DMOG in primary mouse islets.  PHD requires molecular oxygen as a co-substrate; therefore, 
inhibition of PHD via DMOG represents less oxygen being consumed by PHD for activity.    
ATP production and oxygen consumption by mitochondrial respiration is linked to GSIS 
and appears to reach saturation at 16mM glucose in the pancreas.
121
 Chronically elevated glucose 
levels that are characteristic of T2D leads to β-cell compensation and an increase in oxidative 
metabolism with a subsequent increase in OCR levels.
7
 Therefore, decreased OCR levels with 
DMOG treatment suggests that 832/13 cells and primary mouse islets display more efficient 
GSIS compared to NT.  As well, TCA cycle intermediates, notably citrate and isocitrate, increase 
in response to a glucose stimulus and lead to enhanced GSIS.
121
 It is hypothesized that increased 
TCA cycle intermediates in response to glucose are involved in futile pyruvate cycling, 
generating cytosolic αKG.  Cytosolic αKG acts as a co-substrate for PHD and may be involved 
in regulating GSIS.  However, chronic hyperglycemia, a hallmark of T2D, impairs oxidative 
metabolism subsequently leading to reduced ATP production and GSIS.
120
 Alarcon and 




proinsulin concentration.  Proinsulin biosynthesis in the ER, the precursor to insulin, was found 
to be increased with HG, linking oxidative metabolism to GSIS.
122
   
  PHD inhibition reduced oxidative metabolism in both 832/13 cells and primary mouse islets 
when stimulated with HG (16.7mM) KRB, altering parameters that indicate mitochondrial 
function and viability.  In vitro and in vivo experiments assessing GSIS resulted in increases 
insulin secretion when PHD is inhibited in rodent models.  Therefore, reduced OCR levels when 
PHD is inhibited suggest better mitochondrial efficiency.  Further research is needed to 
determine if these results hold true for human islets and to determine the mechanisms by which 









Figure 5.1: ATP production by oxidative metabolism. 
Reducing equivalents from the TCA cycle enter the ETC via complex I and complex II.  Electron 
flow pumps H
+ 
ions into the intermembrane space, generating the proton motive force.  H
+
 ions 
produce ATP in the mitochondrial matrix via ATP synthase.  H
+
 may also be dissipated as heat 
and does not contribute to ATP production.  Image was reproduced from Servier Medical Art by 
Servier, licensed under CC BY 3.0.  
5.4 Insulin secretion in male C57BL/6J primary mouse islets 
5.4.1 In vitro findings from GSIS assays in primary mouse islets 
 Inhibition of PHD via 5mM DMOG led to alterations in glucose-stimulated 




This suggests that PHD inhibition decreases the KATP channel-dependent pathway by decreasing 
the ATP/ADP ratio.  OCR levels were measured in real time and were reduced throughout the 
entire time period, suggesting that PHD is involved in KATP channel-independent pathways.  
These findings may lead to changes in insulin secretion.  The acute effects of DMOG treated 
islets in static GSIS were next assessed.  Primary islets were treated with 5mM DMOG for one 
hour stimulated with LG (2mM) KRB or HG (16.7mM) KRB compared to NT.  There was an 
increased trend in increased insulin secretion with 5mM DMOG stimulated with HG (16.7mM) 
KRB.    
 
5.4.2 In vitro findings from perifusion assays in primary mouse islets 
 Inhibition of PHD via DMOG alters mitochondrial metabolism by decreasing OCR levels 
alluding to alterations in KATP channel-independent pathways in both 832/13 cells and primary 
mouse islets.   5mM DMOG increased static insulin secretion in primary mouse islets via an 
insulin secretion assay when islets were stimulated with HG (16.7mM) KRB.  A perifusion assay 
was performed in islets treated with 5mM DMOG to distinguish between first- and second-phase 
GSIS.  There was a reduced trend in insulin secretion when DMOG treatment was initiated in 
primary islets with HG (16.7mM) KRB.  These findings, along with reduced ATP turnover, 
suggest that inhibition of PHD via DMOG leads to reduced insulin secretion via the KATP 
channel-dependent pathway.  It cannot be eliminated that PHD may alter first-phase insulin 
secretion, which occurs within the first 10 minutes after glucose stimulation.  However, PHD 
may play a greater role in KATP channel-independent pathways through anaplerosis.  There was a 
statistically significant increase in insulin secretion in islets treated with DMOG in the latter 30 




5.4.3 In vivo findings from ipGTTs in primary mouse islets 
 Acute systemic effects of PHDs were assessed by ipGTTs.  Blood glucose levels were 
measured over a two hour period in C57BL/6J male mice aged 10-14 weeks injected with 
200µg/g body weight DMOG compared to PBS controls.  In vitro experiments using primary 
mouse islets treated with DMOG resulted in increased GSIS.  It was hypothesized that C57BL/6J 
male mice injected with DMOG would display similar findings in vivo.  Inhibition of PHD via 
DMOG resulted in decreased blood glucose levels at 90 and 120 minutes after an exogenous 
glucose load.  Blood glucose levels remained unchanged in the first 30 minutes after a glucose 
challenge.  Plasma insulin samples were collected at baseline, 10 and 30 minutes after glucose 
injection and an ELISA was performed to measure plasma insulin levels.  Plasma insulin levels 
were significantly reduced in mice injected with DMOG at 10 minutes despite unchanged blood 
glucose levels.   
The results discussed in chapter four suggest that PHD plays a role in both first- and 
second-phase GSIS.  Mice injected with 200µg/g BW DMOG showed improved glucose 
tolerance at 90 and 120 minutes and improved insulin sensitivity at 10 minutes.  
 
5.4.4 PHD inhibition via DMOG alters first- and second-phase insulin secretion 
 In vitro insulin secretion assays and in vivo ipGTTs demonstrate that acute inhibition of 
PHD leads to alterations in insulin secretion; however the exact mechanism remains 
inconclusive.  There are three pyruvate cycling pathways producing NADPH and αKG that may 
be involved in the regulation of GSIS.
123
 There is evidence that increased cytosolic αKG leads to 
sustained second-phase insulin release.
123
 C57BL/6N mice fed a HFD showed reduced serum 




in a T2D rodent model.
124
 CIC, which transports citrate and isocitrate to the cytosol, and ICDc, 
which catalyzes the conversion of isocitrate to αKG and producing NADPH, are involved in 
GSIS.
109,123
 Inhibition of CIC in 832/13 cells and primary rat islets using the pharmacological 
inhibitor 1,2,3-benzenetricarboxylate (BTC) significantly inhibited first- and second-phase 
insulin secretion.
109
 siRNA knockdown of ICDc in 832/13 cells and primary rat islets also led to 
a significant reduction in GSIS.
111
 However, Guay et al. (2013) found that ICDc negatively 
regulated GSIS in 832/13 cells and primary rat islets.  RNAi knockdown of ICDc in 832/13 cells 
and primary rat islets resulted in enhanced GSIS with unaltered glucose metabolism.
125
 
Inhibition of ICDc increased mitochondrial isocitrate, acetyl-CoA and ATP and it is suggested 
that increased mitochondrial TCA cycle intermediates is coupled with increased GSIS.
125
          
 Currently, there is no specific role of cytosolic αKG in the pyruvate/isocitrate 
pathway.
48,123
 αKG is a known co-substrate for PHD and it is suggested that PHD plays a role in 
GSIS.  It is hypothesized that PHD may be one mechanism by which αKG regulates GSIS.  
832/13 cells and primary rat islets were treated with the PHD inhibitor EDHB, which resulted in 
reduced GSIS.
47,48
 siRNA knockdown for each PHD isoenzyme determined that PHD3 led to a 
greater reduction in GSIS compared to PHD1, and PHD2 did not reduce GSIS in 832/13 cells.
47
  
 Together, in vitro and in vivo experiments presented in this thesis assessing the role of 
PHD in GSIS via DMOG determined the opposite to be true.  These differences could be due to 
variations in drug mechanisms and concentrations.  Fallon and colleagues (2008) observed 
decreased GSIS with 1mM EDHB, an iron chelator, in primary rat islets and Huang and 
colleagues (2016) observed increased GSIS with 50µmol/L EDHB whereas 500µmol/L and 
1000µmol/L EDHB significantly reduced GSIS.  Respiration assays determined that 5mM 




5mM DMOG was continued for insulin secretion assays and there was an increased trend in 
insulin secretion.  It is hypothesized that acute inhibition of PHD leads to enhanced insulin 
secretion, possibly through compensatory mechanisms affecting both first- and second-phase 
insulin secretion.  Mice fed a HFD displayed impaired anaplerosis and reduced αKG levels, 
suggesting that TCA cycle intermediates are reduced in a diet-induced obesity rodent model, 
inhibiting PHD activity and leading to impaired GSIS.
124
 Further research is warranted to 
investigate whether and how long term inhibition of PHD affects GSIS.   
5.5 Protein Identification         
5.5.1 Proline hydroxylation in 832/13 cells  
 Protein was isolated from 832/13 cells treated with LG, HG, leucine + glutamine, 
palmitate, DMOG, DMαKG and NT.  Co-immunoprecipitation was performed using an anti-
hydroxyproline antibody to isolate protein containing hydroxylated proline residues from whole 
cell lysate samples.  Protein samples with hydroxylated proline residues were run on a 
polyacrylamide gel, which was then silver stained to identify band lengths for each treatment.  
Protein bands were excised and delivered to the MALDI-MS Facility at Western University for 
protein identification by MALD-MS.  However, Proteins containing proline hydroxylation were 
unable to be identified by MALDI-MS.  Silver staining may be more sensitive than MALDI-MS 
and therefore, the protein concentration was too low to be detected.  Coomassie Brilliant Blue 








5.5.2 Protein identification by MALDI-MS findings 
 Glucose, amino acids and fatty acids were observed to be downregulated compared to 
NT, suggesting that nutrient stimuli regulate prolyl hydroxylated protein expression.  In the 
presence of PHD, prolyl hydroxylated protein appeared to be downregulated upon nutrient 
stimuli.  Previous experiments demonstrated short term inhibition of PHD via DMOG results in 
enhanced second-phase insulin secretion.  It is hypothesized that acute inhibition of PHD will 
result in upregulation of unidentified proteins to increase insulin secretion. 
 PHD, particularly PHD3, hydroxylates and regulates other proteins involved in altering 
glucose metabolism.  However, it is currently unknown how these metabolic changes affect 
pancreatic β-cell insulin secretion.  PHD3 interacts with the E1β subunit of PDH, the enzyme 
that catalyzes the conversion of pyruvate to acetyl-CoA, which feeds into the TCA cycle, 
coupling glycolysis with mitochondrial respiration.
90
 PHD3 positively regulates PDH, however 
not through proline hydroxylation.
90 
PHD3 also regulates pyruvate kinase M2, which catalyzes 
the last step of glycolysis, converting phosphoenolpyruvate and ADP to pyruvate and ATP.
91
 
PHD3 is suggested to act as a co-activator via hydroxylation of PKM2 to enhance PKM2’s 
interaction with HIF1α.
91 
Upregulation of HIF1α results in alterations in glucose metabolism by 
upregulating  genes that reduce oxygen consumption and increase oxygen availability.
91
 PHD3 
plays a role in tumor proliferation and apoptosis that are independent of HIF1α.
81
 Cancer cells 
treated with αKG showed increased cell apoptosis and decreased cell proliferation, which 
occurred independently of HIF1α but required PHD3.
81 
 
PHD3 is involved in the regulation of proteins that may be involved in altering glucose 
metabolism and potentially influence insulin secretion.  From these experiments, it can be 




currently unidentified proteins that may alter insulin secretion.  Experiments discussed in chapter 
four reveal a novel role for PHDs that could be a potential target for drug development in the 
treatment of T2D.  However, further research is needed to explore the mechanisms by which 
PHD regulates insulin secretion and determine which proteins are involved.  The experiments 
discussed investigate the role of PHD in 832/13 cells and primary mouse islets but future work is 
needed to determine if these results translate to human islets. 
5.6 Limitations and future work 
 One limitation of the experiments presented in this thesis is that all experiments apart 
from ipGTTs are performed in vitro.  Isolated islets are removed from their natural environment 
and lack vasculature.  Isolated islets are incubated (37˚C, 5% CO2) for 18-72 hours prior to the 
day of assay.  During this time, the islet core begins to die, particularly in larger islets, due to 
lack of oxygen diffusion.
126
 Islets become less responsive to glucose stimuli, which causes 
impairments in metabolic activity.
126
 However, we were able to perform in vivo ipGTTs to assess 
glucose tolerance in C57BL/6J male mice injected with DMOG and these observations showed 
similar trends to our in vitro experiments.  Plasma insulin levels revealed improved insulin 
sensitivity upon DMOG injection.  Future work should investigate the role of PHDs in insulin 
sensitivity by performing insulin tolerance tests (ITTs) in mice injected with DMOG.  This will 
measure the effects of PHD inhibition on insulin sensitivity over a two hour period, allowing us 
to distinguish between first- and second-phase insulin secretion.   
 Another limitation of the experiments performed is that all experiments involved PHD 
inhibition using a pharmacological inhibitor.  DMOG inhibits all three isoenzymes of PHD; 
therefore we cannot be certain if a specific isoenzyme plays a greater role in the regulation of 




secretion involves the development of a transgenic mouse model using the Cre-lox system.  Our 
lab is currently generating β-cell specific PHD1, PHD2, and PHD3 KO mouse models using Cre 
recombinase.  Future work will involve performing in vitro and in vivo experiments using PHD 
KO mice, allowing us to address the long term effects of PHD in regulating insulin secretion.   
 We were able to conduct experiments using 832/13 cells and primary mouse islets.  
However, differences in islet architecture and metabolic activity between human and rodent 
islets have been addressed.  Our results show strong evidence that PHD plays a role in oxidative 
metabolism and both first- and second-phase insulin secretion.  Moving forward, studies using 
human islets should be performed to investigate if our findings translate to human islets. 
 Prolyl hydroxylated protein was isolated from 832/13 cells and silver staining for 
MALD-MS protein identification was performed.  However, we were unable to identify prolyl 
hydroxylated protein within our samples.  Future work will continue co-immunoprecipitation 
experiments followed by MALDI-MS to identify proteins that may be regulating insulin 
secretion.  Coomassie Brilliant Blue staining is less sensitive and may be more compatible with 
MALD-MS.  Identification of prolyl hydroxylated proteins in 832/13 cells would allow us to 
perform hydroxylation assays to determine which isoenzyme is involved in the hydroxylation of 
these proteins.  Protein identification would provide insight into the mechanisms by which PHD 
regulates insulin secretion and future experiments investigating the role of these proteins in GSIS 
are needed. 
5.7 Significance of the work 
 
 PHDs have been well-studied for their role in the hypoxia response pathway, where HIFα 
upregulates genes including EPO and VEGF that improve blood flow and oxygen availability in 
chronic kidney disease, cardiovascular disease, and cancer.
50,99




hypoxic environment, where HIFα becomes stabilized and forms a heterodimer with HIFβ to 
upregulate genes that promote angiogenesis  and alter glucose metabolism including glycolytic 
enzymes and LDHA.
66
      
 KATP channel-independent pathways involve anaplerosis, where increased production of 
TCA cycle intermediates such as αKG are associated with second-phase insulin secretion.
39,111
 
αKG is produced in the pyruvate/isocitrate pathway which is positively correlated with increased 
GSIS.  However, a defined pathway has not been identified for αKG.  Our results reveal a novel 
pathway for PHD in the regulation of insulin secretion, whereby cytosolic αKG acts as a co-
substrate for PHD, regulating insulin secretion.  
 However, there is conflicting evidence regarding the role of PHD in insulin secretion.  
Pharmacological inhibition of PHD was found to inhibit GSIS in both cells and primary rat 
islets.
47,48
 Our results reveal that short term inhibition of PHD increased GSIS and affects both 
first- and second-phase insulin secretion.  Further research is warranted in defining the 
mechanisms by which PHD affects insulin secretion both acutely and chronically.  Nonetheless, 
PHDs are involved in pathways that are independent of HIFα and are a potential target for the 
treatment of T2D. 
 T2D is now considered a global epidemic and is associated with the development of other 
diseases, including CVD and stroke.
119,127,128
 Currently, there are several approved anti-
hyperglycemic agents that are used to treat and manage T2D that are effective at maintaining 
blood glucose levels.
127
 Anti-hyperglycemic agents target one mechanism of a highly complex 
disease, resulting in patients often being prescribed a combination of agents. As well, emerging 
evidence reveals that these approved agents may be correlated with serious adverse effects and 
the long term use of these agents remains unclear.
127




glucose homeostasis and current anti-hyperglycemic agents targeting the pancreas include 
sulfonylureas and meglitinides, which target the KATP channel-dependent pathway.  There are 
currently no anti-hyperglycemic agents that target KATP channel-independent pathways, which 
contributes 70% of total insulin secretion.
37
  Understanding the mechanisms involved in KATP 
channel-independent pathways is of importance to development effective treatment options for 
T2D.     With the findings presented in this thesis, PHD may be a potential target for drug 
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A.1 Assessing the role of PHD in PHD123fl/fl primary mouse islets using a RIPCre 
adenovirus 
 After islet isolation, approximately 120-150 islets per treatment from PHD123fl/fl male 
mice were picked into 6-well plates containing 2mL of islet growth media.  Islets were infected 
with 2µL of shGFP control virus or RIPCre adenovirus compared to NT.  20mM of glucose was 
added to each well and islets were incubated for 18 hours overnight (37˚C, 5% CO2).  Islets were 
analyzed for GFP and RFP and 60-72 hours after infection, an insulin secretion assay was 
performed.  After GSIS, islets were either snap frozen where protein extraction was performed 
for western blot analysis or insulin secretion was measured by RIA.   
 PHD knockdown was measured by western blot analysis using primary antibodies for 
PHD1, PHD2, PHD3, HIF1α and tubulin as a control.  A significant PHD knockdown for all 
isoenzymes was not detected, which may be due to experimental methods.  This may be due to 
inaccurate concentrations of viruses, incubation time of viral infection or the quality of the 
RIPCre adenovirus, as islets treated with shGFP were 100% infected and islets treated with the 





Figure A.1: PHD knockdown using a RIPCre adenovirus by western blot. 
Total protein was isolated from PHD123fl/fl primary islets.  Protein samples were analyzed by 
western blot for PHD knockdown of all three PHD isoenzymes and HIF1α.  Tubulin was used as 
a control.  Protein samples contained 120-150 islets and protein intensity was measured by 
Imagej.  PHD1 was approximately 44kDa, PHD2 50 kDa, PHD3 47 kDa, HIF1α 132 kDa and 
tubulin 50 kDa. 
 
 To assess whether PHD plays a role in insulin secretion, a GSIS was performed using 
primary islets from PHD123fl/fl male mice treated with a shGFP virus, a RIPCre adenovirus or 
NT.  Islets were treated with LG (2mM) KRB, HG (16.7mM) KRB, LG (2mM) KRB + KCl 
(30mM) + diazoxide (200µM), HG (16.7mM) KRB + KCl (30mM) + diazoxide (200 M) and HG 
(16.7 M) KRB + DMM (10mM) + DMαKG (10mM) in KRB for one hour (37˚C, 5% CO2).  
Insulin secretion was measured by RIA.  A significant difference in insulin secretion in the 




methods, as a measurable difference in protein knockdown by western blot analysis was unable 
to be measured.  It is thought that the RIPCre adenovirus containing Cre recombinase would be 
able to target loxP sites in PHD123fl/fl male mice to induce a knockdown.  PHD knockdown via 
viral infection would be able to determine if PHD plays a role in insulin secretion.   
 
Figure A.2: Islet GSIS in PHD123fl/fl male mice using viral infection. 
shGFP, RIPCre, and NT islets treated with LG (2mM) KRB, HG (16.7mM) KRB, LG (2mM) 
KRB+ KCl (30mM) + diazoxide (200µM), HG (16.7mM) KRB+ KCl (30mM) + diazoxide 
(200µM) and HG (16.7mM) KRB + DMM (10mM) + DMαKG (30mM) for one hour.  (n=6-9).  









A.2 Antibody information 
Table A.1: Primary and secondary antibodies 
Target Clonality Host 
Species 
Application Manufacturer 
PHD1 EPR2745 Rabbit Western 
blot/immunofluorescence 
Abcam 








HIF1α Sc-10790 Rabbit  Western blot Santa Cruz 
Tubulin Monoclonal 
T8328 
Mouse Western blot Sigma 
Insulin Polyclonal 
A0564 
Guinea pig Immunofluorescence Dako 
Alexa Fluor® 
488 






Rabbit Immunofluorescence  ThermoFisher 
Scientific 
Hydroxyproline  Polyclonal 
#37067 
Rabbit Co-immunoprecipitation Abcam 
 
A.3 Primer information 
 
Table A.2: Primers for genotyping 











 Reverse GGAGCTGGAGTTCTAGGTCAGGTT 24   




 Reverse AGGGGATTTGTAGTTGGCCG 20   









Common GGAAGCAGAATTCCAGATACTTG 23  Jackson 
Laboratories 
 WT  GTCAAACAGCATCTTTGTGGTC 22 488 Jackson 
Laboratories 
 Mutant  GCTGGAAGATGGCGATTAGC 20 675 Jackson 
Laboratories 
 
  
